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Despite therapeutic advances, cancer patients demonstrate an increased risk of 
developing disease- and treatment-related cardiovascular (CV) and metabolic morbidity, 
as compared to their peers. In light of emerging evidence, cancer- and treatment-related 
damage to the autonomic nervous system (ANS) may play a role in the development of 
the aforementioned morbidity risks. This assertion needs to be verified. The purpose of 
this study was to assess the feasibility of conducting concurrent ANS and CV 
evaluations in adolescent and young adult (AYA) cancer patients undergoing treatment 
for various cancers by defining the i) methodological pitfalls and best-practice criteria for 
ANS testing in cancer, and ii) provide initial physiologic evidence of autonomic 
perturbations in cancer patients using the composite autonomic scoring scale (CASS). 
Thirteen patients were assessed, pre-treatment (T1) and following 4 cycles of 
chemotherapy (T2), using CASS and a modified Astrand-Rhyming cycle ergometer 
protocol, and their results compared to 13 sex and age-match controls. Overall, the 
average success rate in achieving the targeted feasibility criteria (FC) was 98.5%. 
Additionally, according to the CASS, there was evidence of ANS impairment at T1 in 5 of 
13 patients, which persisted in 4 of 12 patients at T2, compared to 0 of 13 controls at T1 
and 1 of 12 controls at T2. Using a 2 x 2 repeated measures ANOVA, treatment led to a 
significant improvement in patient heart rate (HR) recovery [F=6.188, p=0.027]. Results 
from this feasibility study suggest the investigation of ANS function in AYA cancer 
patients undergoing chemotherapy is possible, provided the proper precautions are 
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taken. Furthermore, to the best of our knowledge, this is the first study to report evidence 
of ANS impairment using CASS and sudomotor dysfunction in this population. 
 
 
Keywords: Cancer, autonomic nervous system, composite autonomic scoring scale 









 I will begin by extending my sincere appreciation for Dr. Robert Kilgour 
(supervisor) in helping shape this project and for his ongoing guidance and support 
throughout. For over 4 years, juggling this project with full time employment has been 
challenging, but your patience and steady resolve provided the perfect combination of 
reassurance and motivation to help me see it through.  
 
This project would not have been possible without the considerable generosity 
and support of Dr. Ronald Schondorf (co-supervisor). I consider myself blessed to have 
had you a part of my life and am infinitely thankful for the countless hours and content 
you dedicated to both this project and my own personal development. I will hold close 
your exceptional insight and critical approach to clinical research, as I push forward in 
my career. 
 
Similarly, I must extend my heartfelt thanks to Julie Benoit (research assistant). 
Your kind, selfless and steadfast support has had a tremendous impact on this project 
and myself. The extent to which you exceeded your obligation to help cannot be 
overstated. You are a dear friend, and I will always cherish our time together.  
 
On a final professional note, I would like to thank Suzanne O’Brien (Executive 
Director, Hope & Cope), Anouline Sintharaphone (Exercise Program Coordinator, Hope 
& Cope), and my exceptional team within our Rehabilitation and Exercise Oncology 
Program (Hope & Cope). Your tireless support of my academic pursuits can never be 
repaid. Again, I am truly blessed to have been in the company of such dedicated and 
vi 
 
compassionate colleagues. I will forever be proud to have been apart of such an 
incredible family and organization. 
 
To my parents, thank you for always believing and never giving up. Words 
cannot describe how much you mean to me. 
 
To my fiancée and my rock, Rhiannon. Thank you for your patience and 
encouragement. I could not ask for a better friend or partner. I cannot say life will be any 









Table of Contents 
 
 
List of Figures .................................................................................................................. x 
List of Tables .................................................................................................................. xi 
List of Abbreviations ...................................................................................................... xii 
Author Contributions for the Manuscript ........................................................................ xiii 
 
Chapter I ........................................................................................................................ 1 
Cancer Survivorship: The Context of Late Effects .......................................................... 2 
1. Introduction ................................................................................................................. 4 
1.1.1 Burden of Adolescent and Young Adult Cancer in Canada ................................ 4 
1.1.2 Late Effects of Cancer and Related Treatment ................................................... 4 
1.1.3 Societal Burden of AYA Cancer ......................................................................... 6 
1.2 Autonomic Nervous System...................................................................................... 6 
1.2.1 Basic Structure and Function ............................................................................. 6 
1.2.2 Autonomic-Cardiovascular Control ..................................................................... 7 
1.2.3 Clinical Laboratory Assessment of Autonomic Function ....................................10 
1.2.3.1 Respiratory Sinus Arrhythmia .....................................................................11 
1.2.3.2 Valsalva Manoeuvre ...................................................................................14 
1.2.3.3 Tilt-Table Test .............................................................................................17 
1.2.3.4 Heart Rate Variability: Overview and Applications ......................................20 
1.2.3.5 Quantitative Sudomotor Axon Reflex Test ..................................................24 
1.2.3.6 Autonomic Assessment Summary ..............................................................27 
1.3 Cardiovascular Response to Acute Exercise ...........................................................29 
1.3.1 Basic Cardiovascular Structure and Function ....................................................29 
1.3.2 Assessment of Cardiovascular Function ...........................................................29 
1.3.2.1 Maximal and Submaximal Exercise Testing ................................................29 
1.3.2.2 Sources of Error .........................................................................................30 
1.3.2.3 Exercise Test Selection ..............................................................................32 
viii 
 
1.4 Autonomic and Heart Function in Health and Disease: The Role of Exercise ..........33 
1.4.1 Introduction .......................................................................................................34 
1.4.2 Influence of Exercise on Healthy Autonomic and Heart Function ......................35 
1.4.3 Autonomic Dysfunction in Cardiovascular Disease............................................36 
1.4.4 Role of Exercise in Preserving or Restoring Autonomic Function ......................36 
1.5 Impact of Cancer on Autonomic and Cardiovascular Function .................................38 
1.5.1 Introduction .......................................................................................................38 
1.5.2 Impact of Cancer on Autonomic Function ..........................................................38 
1.5.3 Impact of Cancer on Cardiovascular Function ...................................................39 
1.5.4 Chemotherapy: Mechanisms, Risks and Limitations .........................................39 
1.5.5 Impact of Chemotherapy on Autonomic Function ..............................................41 
1.5.5.1 Chemotherapy-Induced Autonomic and Peripheral Neurotoxicity ...............41 
1.5.5.2 Autonomic Testing During and Post Chemotherapy....................................42 
1.5.6 Impact of Chemotherapy on Cardiovascular Function .......................................43 
 
Chapter II ......................................................................................................................44 
Rationale and Clinical Significance ................................................................................45 
 
Chapter III .....................................................................................................................47 
Research Objectives and Hypotheses ...........................................................................48 
 
Chapter IV .....................................................................................................................49 
Introduction ...................................................................................................................50 
Methods ........................................................................................................................53 
Participants and Setting .............................................................................................53 
Study Design and Procedure .....................................................................................54 
Feasibility Analysis .....................................................................................................58 
Data Analysis .............................................................................................................60 
Results ..........................................................................................................................60 
Subjects .....................................................................................................................60 
Feasibility Outcomes ..................................................................................................63 
Autonomic Testing: CASS ..........................................................................................73 
ix 
 
CASS Component Results .....................................................................................73 
Global CASS Results .............................................................................................78 
Exercise Testing: Modified Astrand-Rhyming Cycle Ergometer ..................................79 
Discussion .....................................................................................................................79 
Feasibility of Autonomic Testing in Cancer.................................................................79 
Methodological Considerations: Autonomic and Cardiovascular Testing in Cancer....80 
Autonomic Function in Cancer ...................................................................................82 
Conclusion ....................................................................................................................86 
References ....................................................................................................................88 
Appendix A .................................................................................................................. 105 
Appendix B .................................................................................................................. 106 





List of Figures 
Figure 1: 5-Year Survival of Patients with Cancer by Era ............................................... 5 
Figure 2: Improvement in 5-Year Relative Survival ......................................................... 5 
Figure 3: Basic RSA physiology.....................................................................................13 
Figure 4: Normal and abnormal HR and BP responses to controlled deep breathing .....14 
Figure 5: BP response to the VM ...................................................................................16 
Figure 6: Normal and abnormal HR and BP responses to VM .......................................17 
Figure 7: Pathway of orthostatic compensation .............................................................19 
Figure 8: Normal and abnormal HR and BP responses to 80o head-up tilt .....................20 
Figure 9: Arterial BP, R-R Interval, and ECG .................................................................21 
Figure 10: Power spectral analysis of HRV ....................................................................23 
Figure 11: Acetylcholine-mediated iontophoresis ...........................................................25 
Figure 12: Normal and abnormal postganglionic sudomotor sweat responses...............26 
Figure 13: Sequence of tests .........................................................................................55 
Figure 14: Subject recruitment .......................................................................................62 
Figure 15: Overview of patient diagnoses by phase.......................................................65 
Figure 16: Patient eligibility by phase ............................................................................66 
Figure 17: Combined incidence of medication use at T1 and T2....................................73 
Figure 18: Use of PCMs by phase .................................................................................73 
Figure 19: RSA results ..................................................................................................75 
Figure 20: VR results .....................................................................................................76 
Figure 21: QSART results - Forearm .............................................................................76 
Figure 22: QSART results - Proximal leg .......................................................................77 
Figure 23: QSART results - Distal leg ............................................................................77 
Figure 24: QSART results - Foot ...................................................................................78 
xi 
 
List of Tables 
Table 1: Mechanical and Hemodynamic Response to Valsalva .....................................15 
Table 2: Expected BP & HR Response to Head-Up Tilt .................................................19 
Table 3: Time Domain Measures of HRV ......................................................................22 
Table 4: Relevant Feasibility Endpoints (Exercise Oncology) ........................................59 
Table 5: Reported vs. Required Feasibility Criteria ........................................................59 
Table 6: Subject Characteristics (T1) .............................................................................61 
Table 7: Patient Demographics .....................................................................................61 
Table 8: Patient Recruitment & Access ..........................................................................64 
Table 9: Patient Retention Rates ...................................................................................67 
Table 10: T1 Testing Opportunity ..................................................................................68 
Table 11: Patient Testing Performance and Tolerability .................................................71 
Table 12: CASS Component Scores .............................................................................75 






List of Abbreviations 
ADL - Activities of Daily Living 
AE - Adverse Events 
ANS - Autonomic Nervous System 
AV - Atrioventricular 
AYA - Adolescent and Young Adult 
BFI - Brief Fatigue Inventory 
BMI - Body Mass Index 
BP - Blood Pressure 
bpm - Beats Per Minute 
CAN - Central Autonomic Network 
CASS - Composite Autonomic Scoring Scale 
CO - Cardiac Output 
CV - Cardiovascular 
CVD - Cardiovascular Disease 
CVRC - Cardiovascular Reserve Capacity  
DOX - Doxorubicin 
Dx - Diagnosis 
FC - Feasibility Criteria 
HF - High Frequency 
HR - Heart Rate 
HRV - Heart Rate Variability 
JGH - Jewish General Hospital 
LF - Low Frequency 
ME - Maximal Exercise 
MSRC - Musculoskeletal Reserve Capacity 
NR - Not Reported  
NS - Nervous System  
O2 - Oxygen  
OEP - Otherwise Eligible Patients 
PA - Physical Activity – PA 
PCM – Potentially Confounding Medication 
PNS - Parasympathetic Nervous System – PNS 
Pt – Patients 
QSART - Quantitative Sudomotor Axon Reflex Test 
RPE - Rate of Perceived Exertion 
RSA - Respiratory Sinus Arrhythmia 
SA - Sino-atrial 
SD - Standard Deviation 
SME - Sub-Maximal Exercise 
SNS - Sympathetic Nervous System 
T1 - Pre-Treatment or Baseline 
T2 - Follow-Up 
VM - Valsalva Maneuver 
VO2max - Maximal O2 Uptake 





Author Contributions for the Manuscript 
 
Scott Adams is the primary author of the manuscript included in this thesis and is 
responsible for subject recruitment, data collection and data analysis. He is also 
responsible for the writing of the thesis chapters preceding the manuscript. 
 
Robert Kilgour is the main thesis supervisor to the primary author and oversaw the 
development of the project and the manuscript. Dr. Kilgour assisted in editing the entire 
thesis and manuscript. 
 
Ronald Schondorf is the co-supervisor and laboratory supervisor to the primary author. 
Dr. Schondorf made a significant contribution to the theoretical, data collection and data 
analysis components of the thesis. Furthermore, Dr. Schondorf provided critically 
important intellectual content to the interpretation of the results and is the primary editor 
of the manuscript ensuring its accurateness and completeness. 
 
Julie Benoit is responsible for supervising and assisting in data collection, data cleaning 

























Cancer Survivorship: The Context of Late Effects 
Engaging in regular exercise has been shown to enhance the function of almost 
every human system, including, but not limited to, the CV, musculoskeletal, endocrine, 
nervous, reproductive and gastrointestinal systems. Since the first studies were 
published in the mid-1980’s, engaging in regular exercise has been shown to improve 
cancer prevention, management and recovery outcomes. Given cancer’s heterogeneity, 
elucidating mechanisms by which exercise may benefit cancer patients continues to 
prove elusive. Unraveling the overlapping influences of patients’ environment, genetics, 
behavior, lifestyle, pre-existing and age-related comorbidities from their specific cancer 
diagnoses and the multitude of surgical, local and systemic anti-cancer therapies is 
difficult. Nonetheless, many researchers are working to advance our understanding of 
key cancer-exercise risk factors, mechanisms of dysfunction and therapeutic benefits. 
 
Recent reviews of the long-term impact of common cancer therapies from the 
1970’s to the 1990’s have provided important epidemiological information regarding the 
late effects of treatment. These cancer survivors have a significantly increased risk of 
CV, metabolic, cognitive and functional impairments (Section 1.1.2). Improved 
diagnostic and screening techniques, surgical advances and new treatments (Section 
1.1 & 1.5) have dramatically improved survival rates but the late-effects of treatment, 
combined with natural age-related comorbidities, may pose serious risks for these 
survivors. As such, greater emphasis should be placed on developing and improving 
follow-up and related comorbidity prevention strategies. 
 
Some of these strategies can be inferred from the related risk factors that exist 
for developing CV/metabolic diseases and cancer, as well as for developing CV and 
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metabolic sequelae years after the cessation of cancer therapy (Demark-Wahnefried, 
Aziz, Rowland, & Pinto, 2005). These common risk factors do not establish a true cause 
and effect relationship between developing cancer and CV and metabolic morbidity. 
Nonetheless, it would stand to reason that any strategy known to improve CV function 
should at least be considered in patients with cancer. 
 
One possible common link may be the effect of cancer its therapy on ANS 
function. A relationship between indices of autonomic function and the incidence and 
severity of CV morbidity is well supported in the literature. Whether poor autonomic 
function causes, or simply predicts CV morbidity has not been well defined. If a causal 
relationship exists, the preservation and restoration of autonomic function may prevent 
the development of CV and metabolic comorbidities (Section 1.4). Alternatively, the 
assessment of autonomic function in cancer patients and survivors may provide 
important prognostic information regarding future CV morbidity. Thus far, the evaluation 
and reporting of cancer-related ANS impairment has been inconsistent (Section 1.5) 
and has been hampered by the wide age range of patients studied. Since ANS function 
naturally declines with age, investigations using a younger population should better 
highlight any influence of cancer and anticancer therapies on ANS function.  
 
We have extensive experience with these younger patients who are treated 
within the McGill AYA Oncology Program. We know that despite the presence of 
recurrent and advanced disease (42% of study participants), these patients remain 
highly motivated and compliant with exercise prescriptions (Dalzell et al., 2010). These 
factors, coupled with the general lack of age related comorbidity make them a 
physiologically ideal cohort to begin assessing incidence and mechanisms of cancer-




1.1.1 Burden of Adolescent and Young Adult Cancer in Canada 
In general, AYAs face a unique subset of life stage-related issues and challenges 
to self-identity, relationships, fertility, personal and financial independence (Zebrack et 
al., 2013). A cancer diagnosis (Dx) makes these issues even more burdensome and 
difficult to confront. In recent years, evidence has emerged highlighting multiple 
healthcare- and support-disparities between the AYA cancer age group and their 
younger and older oncology counterparts (Bleyer, 2007). One hundred thousand new 
AYA cancer diagnoses (aged 20-44 years) were reported in Canada between 1990 and 
1999 (Ontario, 2006). Although it is true that 5-year survival rates (Figure 1) (72% 
survival men & 81% women (Ontario, 2006)) in this group have been quite high, these 
rates have not changed since the mid 1970’s (Figure 2). In contrast, survival rates of 
younger and older patient groups have improved. The reasons for this distinction are 
unclear. Perhaps the tumour biology and physiology is different (Bleyer et al., 2008), or 
perhaps these patients have fallen between the cracks in the healthcare system as 
evidenced by the late diagnosis of their cancer (Section 1.1.2), poor tracking and 
enrolment in AYA clinical trials, treatment centres and support programs (Bleyer, 2007). 
 
1.1.2 Late Effects of Cancer and Related Treatment 
As noted above, diagnosis of cancer in the AYA group is often delayed (Bleyer, 
2002, 2007). As a result of these delays cancers are often more advanced at diagnosis 
and more aggressive treatment strategies are often required. These treatments often 






Figure 1: 5-Year Survival of Patients with Cancer by Era, SEER, 1975-1998 






Figure 2: Improvement in 5-Year Relative Survival, Invasive Cancer, SEER, 1975-1997 
(National Institutes of Health, 2006) 
 
serious psychosocial issues, heart disease, stroke, diabetes, hypertension, dyslipidemia, 
obesity, renal insufficiency, subsequent malignancies, and decreased muscle mass 
(Demark-Wahnefried et al., 2005; Oeffinger, Nathan, & Kremer, 2010). Studies of 
pediatric cancer survivorship have highlighted the following alarming trends: i) 
approximately ¾ of survivors will develop a chronic disease by age forty, with >40% of 
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those diseases being serious (Geenen et al., 2007; Oeffinger et al., 2006), ii) even 30 
years or more after post Dx, there is a significantly increased risk of premature death 
(from a second cancer or cardiopulmonary disease) (Mertens et al., 2001; Moller et al., 
2001) and iii) approximately 50% of long term survivors will experience diminished 
health status (moderate to severe) (Hudson et al., 2003; Ness et al., 2005).  
 
1.1.3 Societal Burden of AYA Cancer 
As a result of persistent disease and treatment-related damage, AYA cancer 
survivors may be at risk of long-term complications impacting their health, quality of life 
(QOL), functional independence, and may seriously hinder their ability to reintegrate and 
meaningfully contribute to society. Combining incidence, 5-year survival, and mortality 
data (Canada, 2012; Ontario, 2006) with average life expectancy (Canada, 2012), crude 
calculations approximate that, every year, the lingering effects of new Canadian AYA 
cancer diagnoses have the potential to impact over 350,000 years of productive adult life 
(see Appendix A for calculation summary). This represents a tremendous burden to 
society. Furthermore, it underscores the importance of developing and implementing 
prevention strategies targeting these late effects. However, before targeted strategies 




1.2 Autonomic Nervous System  
1.2.1 Basic Structure and Function 
 The ANS exerts control over visceral functions at multiple levels. The central 
autonomic network (CAN) is comprised of multiple, reciprocally interconnected areas 
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within the hypothalamus, brain stem and spinal cord. The CAN serves as the reception 
and integration center for afferent visceral, humoral and environmental stimuli and elicits 
coordinated reflex responses via efferent preganglionic autonomic, neuroendocrine, 
respiratory and sphincter motoneurons. These tonic and adaptive reflex responses are 
relayed to effector organs via the parasympathetic and sympathetic ANS branches and 
are influenced by a variety of internal and external environmental states and stimuli (e.g. 
circadian, postural, acute exercise or emotional factors) (Benarroch, 1997; Guyton & 
Hall, 2006a). 
 
 The parasympathetic nervous system (PNS) and sympathetic nervous system 
(SNS) are distinctly different in both structure and function. Structurally, the functional 
unit of the PNS is comprised of long, myelinated preganglionic efferent fibers that 
synapse with short unmyelinated postganglionic neurons. These PNS relay ganglia are 
typically found in close proximity to or within the individual organs they innervate. 
Conversely, the SNS is comprised of shorter myelinated preganglionic neurons that 
synapse with longer unmyelinated postganglionic neurons. Unlike the PNS relay ganglia, 
the divergent efferent fibers leading away from the SNS relay ganglia innervate multiple 
effector organs and organ regions. According to these structural differences, damage to 
SNS relay ganglia or postganglionic fibers may manifest as multi-organ or systemic 
failure, whereas typical presentation of postganglionic PNS damage is more localized 
(Guyton & Hall, 2006a; Harati & Machkhas, 1997). 
 
1.2.2 Autonomic-Cardiovascular Control  
The CV system is comprised of the heart, lungs, peripheral vasculature and 
blood. As a functional unit, the CV system continuously adjusts to maintain organ blood 
flow and peripheral oxygen (O2) delivery via regulation of cardiac output (CO) and 
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systemic vascular resistance. This dynamic and finely tuned CV control is achieved 
through the synergistic action of both PNS and SNS branches on key effector organs 
(e.g. heart and lungs), as well as CAN-mediated neuroendocrine effects and local 
factors (Joyner & Shephard, 1997). 
 
Various local and neural mechanisms influence CO, including venous return (the 
Frank-Starling mechanism), local and peripheral tissue metabolic demands, systemic 
vascular resistance and respiration rate (Guyton & Hall, 2006b). HR is intrinsically driven 
by both an intrinsic cardiac nervous network (similar to the enteric nervous system (NS) 
of the gut (Randall et al., 2003)) and the periodic, spontaneous depolarizations of the 
sino-atrial (SA) node (Yasuma & Hayano, 2004). The SA node, the atrioventricular (AV) 
node, and the atrial and ventricular (SNS only) myocardium, are dually innervated and 
modulated by the PNS and SNS. In general regulatory or homeostatic terms, stimulation 
from the SNS increases CO by increasing ventricular contractility or the rate of cardiac 
depolarization (Berntson, Cacioppo, & Quigley, 1993; Yasuma & Hayano, 2004). 
Conversely, stimulation from the PNS acts in a reciprocal manner to effectively decrease 
HR, cardiac muscle conduction, atrial contractility and ventricular contractility via the 
counteraction, and reflex-dependant inhibition, of the SNS (Randall et al., 2003; Yasuma 
& Hayano, 2004). Beyond the classic ‘opposite and reciprocal’ ANS branch function 
characterization, multiple animal studies have demonstrated that specific and perhaps 
protective autonomic reflex responses to peripheral chemoreceptor, startle, pain and 
ocular trauma stimuli elicit co-activation of the autonomic branches (Patton, Vogel, & 
Mello, 1982). These co-activation states have been shown to elicit biphasic (i.e. startle 
(Abdeen, Taylor, Youngblood, & Printz, 1995; Baudrie, Tulen, Blanc, & Elghozi, 1997; 
Casto, Nguyen, & Printz, 1989; Casto & Printz, 1990; Haroutunian & Campbell, 1982)), 
tachycardic (i.e. somatic nociceptors (Abram, Kostreva, Hopp, & Kampine, 1983; 
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Adams, Baccelli, Mancia, & Zanchetti, 1969; Barr, 1998; Boscan & Paton, 2001; Martin, 
Sutherland, & Zbrozyna, 1976)) and bradycardic (i.e. peripheral chemoreceptor (Kollai & 
Koizumi, 1979)) HR responses. Also under ANS control, HR is further affected by local 
and peripheral reflex responses and by fluctuations in respiration rate (Berntson et al., 
1993; Yasuma & Hayano, 2004). These dynamic and synergistic mechanisms of control 
are necessary to quickly and efficiently adapt the heart’s chronotropic, inotropic and 
dromotropic parameters to the body’s dynamic metabolic needs and various 
environmental stimuli. Importantly, the reciprocal activation and coactivation patterns of 
ANS control play important complementary roles. Reciprocal activation is known to 
evoke rapid reflex adjustments whereas coactivated responses permit greater response 
precision. 
 
Our understanding CV reserve capacity (RC) began with mechanisms identified 
in the heart (Frank, 1895; Starling & Visscher, 1927). We now know this CVRC, inclusive 
of multiple CV system components, protects our functional capacity against varying 
degrees of pathological insult by way of coordinated adaptation (Hsia, 2001). However, 
the adaptive potential of our CV system is not limitless. As such, repeated pathologic 
injury to any (or multiple) system component(s) or chronic pathologic perturbations may 
eventually result in dysfunction. In humans, initial evidence of impairment to either ANS 
branch typically presents within the effector organ(s) they innervate (Ziegler, 1999). Two 
of the many systems affected by autonomic neuropathies are the CV (or O2 transport 
system) and the sudomotor system (Vinik, Maser, Mitchell, & Freeman, 2003). If 
damaged, the resulting decrease in muscle O2 availability and metabolic waste product 
clearance or thermoregulatory impairment could negatively impact functional 
performance, independence and quality of life. Although ANS dysfunction is known to 
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affect systems other than the CV and sudomotor systems, their relative ease of 
measurement provides a safe and tolerable means of autonomic assessment. 
 
1.2.3 Clinical Laboratory Assessment of Autonomic Function 
 The assessment of autonomic function in humans is complex because autonomic 
control, like most control systems, is a closed loop and hence individual components 
such as heart rate or blood pressure do not exist in isolation. Furthermore, due to the 
invasiveness of the procedures required, the direct measurement of ANS activity in 
conscious humans is either difficult or impossible. Accordingly, human investigations of 
ANS function rely on indirect assessment techniques and are therefore subject to 
additional sources error. Although a variety of laboratory and clinical autonomic 
challenges and interpretation techniques have been developed, none are without 
limitations (several of which are described briefly here). 
 
 Clinical investigations of human autonomic function impose simple, non-invasive, 
physiologic challenges, such as the ones described below, in an attempt to elicit 
predictably patterned reflex responses. Despite the apparent simplicity of the imposed 
challenges, even the simplest reflex response is quite complex. Stimuli are registered by 
somatic sensory organs, relayed along afferent nerve fibers to the CAN for processing, 
are processed along with afferent information from other receptor groups, and are then 
transmitted along efferent nerves to the appropriate effector organs. Damage or 
dysfunction within any one of these structures may impact the resultant reflex response. 
Further complicating the issue, there are currently no available means of quantifying the 
inputs to the multiple receptor groups that mediate, these complex reflex responses. The 
underlying physiology is often incompletely understood and some use complex 
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mathematical models, which may not accurately characterize specific ANS branch 
activity.  
 
 Despite the multitude of potential confounders and our current inability to 
quantitate and control the physiologic strain imposed by clinical autonomic challenges, 
the presence or absence of predictable autonomic adjustments may still provide 
important prognostic and diagnostic information. Although an exhaustive discussion of 
ANS testing is beyond the scope of this review, a brief summary of the general 
characteristics of several clinical autonomic challenges is provided below. 
 
1.2.3.1 Respiratory Sinus Arrhythmia 
 Respiration (both depth and frequency of breathing) strongly modulates HR 
rhythmicity generating a rhythm known as respiratory sinus arrhythmia (RSA) (Figure 3) 
(Berntson et al., 1993). This phenomenon results from, and is modulated by, the 
complex interaction of factors originating in the heart (the Bainbridge stretch reflex), 
lungs (the Hering-Breuer stretch reflex), CAN (inspiration-associated inhibition of vagal 
efferents within the medullary respiratory center) and vasculature (respiration-associated 
tonic and phasic baroreceptor and chemoreceptor modulations), as well as local 
mechanical and metabolic factors (Davies & Neilson, 1967a, 1967b; Feldman & 
Ellenberger, 1988; Grossman, 1983; Guyton & Hall, 2006a; McArdle, Katch, & Katch, 
2007; Saul, Rea, Eckberg, Berger, & Cohen, 1990). 
 
RSA naturally occurs across a range of respiratory frequencies but is most 
commonly assessed through the analysis of the frequency and amplitude of HR 
variability (V) during controlled deep breathing. This indirect index of cardiovagal 
function has been suggested to be specific, sensitive and reproducible (Freeman, 1997). 
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Described in dogs (Katona & Jih, 1975), and later in humans (Fouad, Tarazi, Ferrario, 
Fighaly, & Alicandri, 1984), parasympathetic cardiac control is characterized as the 
decrease in HR period resulting from eliminated parasympathetic influence (with 
preserved sympathetic influence). RSA is defined as the peak-to-trough difference in RR 
interval in a series of respiratory cycles (Freeman, 1997). RSA is typically performed 
with the patient supine, where, due to a decrease in baroreceptor-mediated sympathetic 
activity, vagal influence is greatest. The greatest amplitude of RSA-mediated HR 
response is achieved with maximal respiratory effort and at a respiratory rate of four 
cycles per minute. 
 
Although a range of respiratory cycles have been used, RSA is most commonly 
assessed using a comfortably slow respiration rate of six cycles per minute and the 
average peak-to-trough difference from the largest six sequential responses (Freeman, 
1997). Through a range of respiratory frequencies, the R-R interval is shortened when 
the cardiac vagal nerve activity is nearly arrested during inspiration and lengthened 
during expiration when cardiac vagal nerve activity reaches its peak (Figure 3). Although 
some groups have generally consider RSA as a reliable, clinical index of cardiac vagal 
activity (European Society of Cardiology & North American Society of Pacing 
Electrophysiology, 1996; Yasuma & Hayano, 2004), several other factors have been 
shown to modify this reflex response (i.e. state-dependant sympathetic influences, 
circulating catecholamine levels, central and peripheral chemoreceptor stimuli and 
respiratory-linked mechanical factors (i.e. atrial stretch) (Taylor, Myers, Halliwill, Seidel, 





Figure 3: Basic RSA physiology 
(Verrier & Tan, 2009) 
 
 Clinically, the magnitude of R-R difference during inspiration and expiration 
indicates the amplitude of RSA (Eckberg, 1983; Katona & Jih, 1975). This amplitude is 
quantified through high frequency (HF) component spectral analysis of 
electrocardiographic recordings in the range of (0.15 Hz – 0.80 Hz) (Yasuma & Hayano, 
2004). Age related trends show the amplitude of RSA is greatest in younger populations 
and is attenuated with age (Hrushesky, Fader, Schmitt, & Gilbertsen, 1984). Within a 
given age group, well-trained individuals have greater RSA amplitude than their 
untrained counterparts (Dixon, Kamath, McCartney, & Fallen, 1992; Goldsmith, Bigger, 
Steinman, & Fleiss, 1992a). Reduction of RSA (Figure: 4) has been reported in patients 
with coronary artery disease or congestive heart failure (Airaksinen, Ikaheimo, 
Linnaluoto, Niemela, & Takkunen, 1987; Hayano et al., 1990; Myers et al., 1986) and is 
suggested to be one of the most easily quantified markers of autonomic neuropathy in 











Figure 4: Normal and abnormal HR and BP responses to controlled deep breathing (6 breaths/min) 
(Clinical data – Schondorf, 2013) 
 
1.2.3.2 Valsalva Manoeuvre 
 In his book published in 1704, physician Antonio Maria Valsalva first described a 
technique for clearing foreign bodies from the middle ear via a forced expiration against 
a closed glottis (Junqueira Jr., 2008). Now known as the Valsalva Maneuver (VM), this 
reflex response provides the physiological basis for our understanding of CV adaptations 
to forced expiration (Amorim, Manço, Gallo Jr, & Marin, 1982; Eckberg, 1980; Elisberg, 
1963; Freeman, 1997; Junqueira Jr. & Soares, 2002). Despite the VM’s apparent 
simplicity, the resultant reflex response to this challenge is quite complex. The 
physiologic response to the VM is divided into four simultaneous and serially alternating 








Mechanical Factors  Hemodynamic Response 
Phase I 
(inspiration) 
 Aortic compression 






(expiration)   CO (poor venous return)  
 BP (early phase) 
 HR (cardioacceleration) 
 Muscle sympathetic activity 
 Peripheral resistance 
 BP (late phase) 
Phase III 
(relaxation) 
 Cessation of expiration  
 BP 
 HR  
Phase IV 
(relaxation) 
 Residual vasoconstriction 
 Normal venous return  
 BP above baseline 
(overshoot)* 
 HR (baroreflex-mediated) 
* primarily due to cardioacceleration 
Content adapted from (Freeman, 1997) 
 
 Although a variety of variations have been reported, the basic VM is described as 
follows. After two minutes of supine rest, and following a full inspiration, the subject 
breathes into a tube and maintains an expiratory pressure of 40 mmHg for 15 seconds. 
The subject’s beat-to-beat HR and BP responses are collected throughout and in 
recovery from the maneuver. After an additional two minutes rest, the subject is asked to 
perform a second trial (Junqueira Jr., 2008). The multiple, sequential and overlapping 
mechanisms contributing to a normal hemodynamic response to the VM are reasonably 
well understood. Importantly, given the VM’s complexity, many factors have been shown 
to impact the response including (but not limited to) straining initiation, mouth pressure, 
expiratory duration, body position and post-maneuver breathing response. Furthermore, 
the presence and magnitude of the resultant, phase-specific HR and BP responses are 
interdependent. It is this reflex response interdependence which makes it considerably 






Figure 5: BP response to the VM 
(P. Novak, 2011a) 
 
With the understanding that mechanical factors are known to contribute 
throughout, several components of the VM response have been identified as being the 
most informative of ANS control (Eckberg, 1980). Early (Phase I) cardioacceleration 
likely reflects vagal withdrawal, whereas late (Phase IV) HR recovery is thought to be 
influenced by vagal reactivation. Similarly, late Phase II BP recovery is dependant on 
sympathetically-mediated peripheral vasoconstriction, which also influences the Phase 
IV BP overshoot. However, given their interdependence, the analysis or interpretation of 
any singular component of this reflex response is meaningless. Moreover, the VM is 
especially vulnerable to the previously described pitfalls of ANS testing requiring the 
results to be interpreted with caution. A more detailed description of how these 
components contribute to CASS is provided in Section 1.2.3.6. 
 
 Investigation of this maneuver through time-domain indices of HRV and BPV has 
been described as being a sensitive, reliable, reproducible and simple tool in 
approximating cardiac autonomic adjustments in a number of pathologies including: 
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diabetes mellitus (Baldwa & Ewing, 1977; Bennett, Farquhar, Hosking, & Hampton, 
1978), various CV diseases (Rostagno et al., 2000; Trimarco et al., 1983; Tristani, 
Kamper, McDermott, Peters, & Smith, 1977), renal failure (Ewing & Winney, 1975) and 









Figure 6: Normal and abnormal HR and BP responses to VM 
(Clinical data – Schondorf, 2013) 
 
1.2.3.3 Tilt-Table Test 
Utilizing a postural change from supine to upright, a second challenge used to 
assess the integrity of baroreceptor function and its contribution to ANS reflex responses 
is called the tilt-table test. Compared to voluntary standing, the advantage of using the 
tilt-table challenge lies in the partial elimination the voluntary and exertion components, 
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and better control in the event of syncope (Borst, van Brederode, Wieling, van 
Montfrans, & Dunning, 1984; Borst et al., 1982). The assumption of upright posture 
causes a shift of 6-8 ml/kg of blood from the thorax into the abdomen and lower 
extremities (Joyner & Shephard, 1997; Smit, Halliwill, Low, & Wieling, 1999). The blood 
translocation begins immediately, with upwards of 50% of the shift occurring within 
seconds. The resulting reduction in central blood volume decreases cardiac filling 
pressure and ultimately a drop in stroke volume ( 40%) (Smit et al., 1999). Reflex 
tachycardia, likely caused by vagal withdrawal to the SA node and increased 
sympathetic activity, partially compensates for the drop in stroke volume and limits the 
fall in CO to  20%. This cardiac compensation, along with the sympathetically-mediated 
increase in systemic vascular resistance, is able to maintain mean arterial BP. Overall, 
the maintenance of the mean arterial pressure is dependant on a complex series of 
mechanisms including the venoarteriolar axon reflex, pulmonary stretch reflex, 
cardiopulmonary reflexes and arterial baroreflexes (Joyner & Shephard, 1997; Smit et 
al., 1999). 
 
The primary circulatory differences associated with tilt, compared to supine 
circulation, are summarized in Table 2. Beat-to-beat BP and HR changes in response to 
head-up tilt are measured and compared against expected deviations from supine 
measures. Normally, subject BP and HR adaptation takes place within the first 1-2 
minutes of tilt and remains stable until returned to a supine position (typically after 10 






Figure 7: Pathway of orthostatic compensation 
(Yusuf & Camm, 2005) 
 
 
Table 2: Expected BP & HR Response to Head-Up Tilt 
 
Hemodynamic Property Expected Compensation  
Intrathoracic Blood Volume  30% 
Stroke Volume  30-40% 
HR 15-30% 
CO  20% 
Arteriovenous O2 Difference  20% 
Diastolic BP  10% 
Systolic BP Unchanged 
Mean Arterial Pressure  0-10% 


















Figure 8: Normal and abnormal HR and BP responses to 80
o
 head-up tilt 
(Clinic data – Schondorf, 2013) 
 
1.2.3.4 Heart Rate Variability: Overview and Applications 
Physiologically, the fluctuation in R-R intervals (Figure 9) is the result of complex 
interactions between the PNS and SNS and of other non-neurally mediated influences, 
like hormones and intrinsic intracardiac pacemakers. Given that vagal nerve activity 
cannot be directly measured in humans, indirect measures of autonomic function, such 
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as HRV, have become widely used. Beginning with the discoveries of variable beat-to-
beat heart periods (Hales, 1733; von Haller, 1760) and autonomic modulation in both the 
time (Wheeler & Watkins, 1973) and frequency (Sayers, 1973) domains, mathematics-
based HRV analysis techniques have been employed for decades as a non-invasive 
means of approximating the nature of the ANS’s control over the CV system and the 
dynamic nature in which they interact (European Society of Cardiology & North 




Figure 9: Arterial BP (top, mmHg), R-R Interval (middle, ms), and ECG (bottom) 
demonstrates variation of the inter-beat interval 
(de Jong & Randall, 2005) 
 
HRV data is commonly collected under a variety of conditions and settings 
including rest (spontaneous and controlled breathing), in response to known ANS 
challenges (RSA, VM, Head-up Tilt, sustained hand grip, standing, and under emotional 
and mental stress) and over prolonged collection periods (24-Holter monitoring). 
Analysis of time and frequency-based oscillations in heart period require the use of 
increasingly complex mathematical techniques and, in doing so, has been able to 
approximate and make inferences around ANS activity in a host of healthy and disease-
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based physiologic states (Rosenwinkel, Bloomfield, Arwady, & Goldsmith, 2001; Thayer 
& Lane, 2007). Standard time domain indices of HRV are described in Table 3. 
Commonly controlled confounders of HRV collection and analysis include, but are not 
limited to: i) unrecognized ectopic beats, ii) duration and state of collection, iii) 
respiratory frequency and depth, iv) age, v) circadian variation, vi) certain anthropometric 
indices (body weight & body mass index (BMI)), vii) blood gases, viii) physical fitness, ix) 
food ingestion and x) certain medications (especially anticholinergic). Even with 
adequate data collection controls in place, given its complexity and numerous 
confounders, great care must be taken when analyzing and interpreting HRV data.  
 
Table 3: Time Domain Measures of HRV 
 
Measure Definition 
SDNN - Standard deviation (SD) of normal-to-normal (NN) RR intervals (24-hr recordings) 
SDNN index 
- Mean of SD of the RR intervals (5 min segments from 24-hr recordings) 
- Correlates with Very Low Frequency (VLF) (0.0033-0.04 Hz) & Low Frequency (LF)  
 (0.04-0.15 Hz) HR power spectrum 
SDANN index 
- The SD of the mean RR intervals (5 min segments from 24-hr recordings) 
- Correlates with Ultra Low Frequency (ULF) (< 0.0033 Hz) HR power spectrum 
MSSD - The average of the square of the differences between successive HR beats 
rMSSD 
- Square root of MSSD (measure of short term HRV) 
- Correlates with High Frequency (HF) (> 0.15) HR power spectrum 
SDSD - Stand deviation of successive differences 
Content adapted from (Freeman, 1997) 
 
 Frequency-domain analysis of HRV is another commonly used approach to 
quantify ANS activity (Figure 10). Parasympathetic efferent output has been shown to 
be the primary contributor to the HF component of the spectrum through research using 
muscarinic receptor blockades and vagotomies (Akselrod et al., 1981; Malliani, Pagani, 





Figure 10: Power spectral analysis of HRV 
(de Jong & Randall, 2005) 
 
contribution to the low frequency (LF) component of the spectral analysis. Some 
research groups suggest that the LF component is indicative of sympathetic activity 
(Malliani et al., 1991), whereas others argue that it reflects a combination of both 
sympathetic and parasympathetic components (Kamath & Fallen, 1993; Montano et al., 
1994; Rimoldi et al., 1990). It has been suggested that the decrease in absolute power 
of the LF component during some conditions associated with sympathetic activation, 
may explain the overall decrease in total spectral power during sympathetically evoked 
tachycardia (European Society of Cardiology & North American Society of Pacing 
Electrophysiology, 1996).  
 
 Finally, analysis of HRV can provide insight into the physiologic endpoints 
achieved through autonomic control and perhaps some of the underlying 
neurophysiologic mechanisms. However, knowing that these neural mechanisms always 
interact, the interpretation and reporting of HRV findings should avoid definitive claims 
regarding the unique contribution of either ANS branch to the observed response. In this 
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light, this analytical tool may be cautiously used to inform our understanding of ANS 
modulatory changes in cardiac function resulting from various disease- and treatment-
states. 
 
1.2.3.5 Quantitative Sudomotor Axon Reflex Test 
 Controlled by the sudomotor-sympathetic branch of the ANS, sweating is the 
primary mechanism used by our bodies to dissipate heat. Thermoregulation is an ANS-
mediated process that is vital not only to our ability to carry out our activities of daily 
living (Duncan, Howley, & Johnson) but also to our survival. To maintain our body 
temperature within normal homeostatic limits, we rely on continuous input from central 
and peripheral thermoreceptors. These thermoreceptors, located in the preoptic anterior 
hypothalamus, spinal cord, skin and viscera, transmit neural messages to the 
hypothalamic-thermoregulatory center for integration and processing (Low, 2004; 
Schmidt & Chan, 1992). Depending on the type of afferent information, the 
thermoregulatory center will respond with the appropriate efferent reflex response, 
activating pathways meant to either conserve and create or dissipate heat. When 
appropriate, the hypothalamus initiates the sweat response by sending efferent signals 
to the periphery via the preganglionic cholinergic neurons. Synapsing in the 
paravertebral ganglia, and triggered by the release of acetylcholine, depolarization of the 
postganglionic axon stimulates the eccrine glands (M3 muscarinic receptors) to evoke a 
sweat response (Low, 2004; Schmidt & Chan, 1992). Functionally, this sweat response 
acts to cool down the body through evaporative heat loss, the most efficient form of “in 
air” heat dissipation.  
 
Clinically, sudomotor function assessments have been shown useful in localizing, 
diagnosing and monitoring the progression of neurologic disorders resulting from ANS 
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insufficiency. One such sudomotor assessment is called the Quantitative Sudomotor 
Axon Reflex Test (QSART). In each of the four tested QSART sites (medial forearm, 
proximal lateral leg, distal medial leg, and proximal lateral foot), the normal afferent and 
efferent reflex information are relayed along the ulnar, peroneal, saphenous and sural 




Figure 11: Acetylcholine-mediated iontophoresis 
(Schlereth, Brosda, & Birklein, 2005) 
 
the central and preganglionic neural components, using a constant current generator, 
acetylcholine iontophoresis triggers a postganglionic axon reflex-mediated sweat 
response (Figure 11). The sweat response is measured through the quantification of 
humidity changes in the air being passed through the capsule. The site-specific, 
analyzed components of this reflex response are total volume, baseline volume, 
response latency and ending offset volume. The volume components are evaluated and 














Figure 12: Normal and abnormal postganglionic sudomotor sweat responses 
(Clinic data – Schondorf, 2013) 
 
This evaluation can be used as an indicator of postganglionic sudomotor integrity and 
has been shown to be sensitive and reproducible in the testing of diabetics and controls 
(Hoitsma et al., 2004). One of the previously described limitations of using QSART to 
evaluate the integrity of the entire sweat response is that it only measures postganglionic 
sudomotor responses and is unable to identify preganglionic lesions (Illigens & Gibbons, 
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2008). Compared to other sweat tests (i.e. Thermoregulatory Sweat Test), the QSART is 
likely best suited to our purposes because it is well tolerated, requires less time to 
perform, can help to localize lesions to either pre or post-ganglionic and has fewer 
confounders (Fealey, 1997). 
 
Regardless of the mechanism of damage, impairment of this sudomotor axon 
reflex response may place individuals affected at an increased risk of heat injury due to 
their inability to dissipate body heat. In the context of cancer and cancer rehabilitation, 
disease or treatment-related thermoregulatory impairment may similarly predispose 
patients to heat injury and poorer exercise tolerance. 
 
1.2.3.6 Autonomic Assessment Summary 
 Although other ANS-mediated cardiovagal, adrenergic and sudomotor challenges 
exist, the aforementioned autonomic challenges were the best suited to our testing 
purposes. In each case, the specific tests and protocols were chosen on the basis of 
patient tolerance, reproducibility and their complementary contributions to a broader 
understanding of autonomic responsiveness. Furthermore, these challenges are 
commonly used in a clinical battery of ANS challenges and analysed using the 
Composite Autonomic Scoring Scale (CASS) (Low, 1993b).  
 
 Following the completion of all four autonomic challenges, the response data are 
compiled and divided into three component indices (cardiovagal, adrenergic and 
sudomotor). The component score for the cardiovagal index is based on the magnitude 
of the HR response to RSA and the VM (otherwise known as the Valsalva Ratio (VR)). 
The adrenergic index is based on the BP response to Phase II and Phase IV of the VM 
and the BP response to heads-up tilt. The sudomotor index is based on the volume and 
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pattern of the sweat response to QSART. As stated previously, interpretations of indirect 
physiologic measurements are prone to error, especially in the context of single ANS 
challenges being analyzed and interpreted in isolation. As such, CASS was created to 
help provide a global assessment of ANS responsiveness. The cardiomotor, vasomotor 
and sudomotor responses to each challenge provides complementary pieces of 
information that speak to the integrity of each CASS component. The combined 
responses within each component score are then graded based on the severity of 
abnormality (mildly, moderately or severely abnormal).  
 
We anticipate that the study of ANS function in AYAs will have several important 
methodological and theoretical benefits. First, given the heterogeneity of cancer patients 
(diagnoses and treatments), it is essential that other known autonomic testing 
confounders be well controlled. AYAs are expected to not be as likely to experience age 
and comorbidity related declines in ANS reflex responsiveness. This assumption applies 
to both the patient and control groups. As discussed in Section 1.5.5.2, previous cancer-
ANS research has been confounded by the inclusion of subjects with known CV, 
metabolic and NS comorbidities. Knowing that indirect ANS assessment alone cannot 
differentiate between effector organ and autonomic dysfunction, the findings of such 
studies are questionable. Second, the voluntary subject performance instructions may 
be better understood and adhered to than in a younger population. Third, the majority of 
AYA cancer patients will survive many years following their treatments. Knowing that 
they are at an increased risk of CVD development, exercise interventions may be useful 
in controlling said risk. However, ANS function is known to play an important role in 
regulating human exercise responses. As such, cancer and treatment-related ANS 




1.3 Cardiovascular Response to Acute Exercise 
1.3.1 Basic Cardiovascular Structure and Function 
ADL primarily require aerobic, or O2 dependent, work. An individual’s ability to 
perform this type of work is contingent on the efficiency of the O2 transport (blood flow) 
and consumption (mitochondrial) systems. The O2 transport system is multifaceted. 
Coordinated by central, peripheral and neuro-hormonal components of the ANS, its 
overall efficiency is dependent on the synergistic action of the heart, lungs and 
circulatory vessels (arteries, veins and capillaries). The CV and musculoskeletal reserve 
capacities (CVRC and MSRC, respectively) are barely taxed during ADL in healthy 
individuals (Fletcher et al., 2001). However, these reserve capacities can be greatly 
reduced in various disease- and deconditioning-states, thus requiring a larger proportion 
of an afflicted individual’s maximal capacity to carry-out their ADL (Hagberg, 1994). This 
increased exertion is both mentally and physically draining, and serves as a deterrent to 
maintaining activity levels.  
 
1.3.2 Assessment of Cardiovascular Function 
1.3.2.1 Maximal and Submaximal Exercise Testing 
Maximal exercise (ME) tests have been shown to be valid and reliable measures 
of physiological function, such as O2 uptake (VO2) and consumption in skeletal muscle 
and pulmonary function (Fletcher et al., 2001; Shephard et al., 1968). Exercise response 
is maximal when O2 uptake (VO2max) does not increase despite further increases in 
workload (Fletcher et al., 2001; McArdle et al., 2007). The actual VO2max that can be 
attained reflects the delivery capacity of the O2 transport system and the efficiency with 
which O2 is taken up and utilized by working muscles (Hartung, Krock, & Crandall, 
1993). These tests are typically performed on a treadmill or a stationary bicycle. ME 
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methodology described above stands in stark contrast to submaximal exercise (SME) 
tests that rely on predictive equations or extrapolations from physiologic relationships 
(Shephard et al., 1968). ME testing in special populations, such as ours, may not be well 
tolerated for a variety of reasons, including: i) likelihood of pre-VO2max fatigue and 
increased motivational requirement (Noonan & Dean, 2000), ii) incidence cancer-related 
fatigue (Curt et al., 2000) and neuromuscular complications (Chen, Jungsuwadee, Vore, 
Butterfield, & St. Clair, 2007) and iii) the diminished efficiency of the O2 transport system 
(Macvicar, Winningham, & Nickel, 1989). Accordingly, the use of SME testing protocols 
may be more appropriate. In fact, research has shown that ME testing may be 
contraindicated or of little use in a population afflicted with cardiopulmonary, 
neuromuscular or musculoskeletal impairments (Noonan & Dean, 2000). The measures 
of interest in ME testing are used for either diagnostic purposes or in the evaluation of 
treatment outcomes, but the intensity of testing protocols pose a greater relative risk to 
the subjects. Given the difficulty predicting and managing this risk, when testing 
extremely heterogeneous patient groups, SME testing protocols should be used to safely 
and reliably predict or assess the following outcomes: i) the extent of disease or 
treatment-related damage, ii) VO2max, iii) the outcome of therapeutic interventions like 
exercise programs, iv) functional outcomes and v) in making diagnoses (A.C.S.M., 1995; 
Hagberg, 1994; Noonan & Dean, 2000).  
 
1.3.2.2 Sources of Error 
Both ME and SME testing have known sources of error. In ME testing, there are 
inconsistencies in the determination and reporting of VO2max data. Duncan, Howley & 
Johnson (1997) suggested that it is insufficient to use of VO2 plateau as the defining 
criteria for the achievement of VO2max. Their findings, consistent with the literature, 
revealed the attainment of a VO2 plateaus were only indicative of maximal effort in 50% 
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or less of the subjects assessed using continuous protocol methodology, and 60 – 90% 
reached a plateau using the discontinuous protocol (Duncan et al., 1997). Additionally, 
during a ME test, if the aforementioned VO2max criteria are not met, the term used to 
describe the achieved VO2 level should be “VO2peak” (Zeballos & Weisman, 1994). In 
fact, Zeballos and Weisman (1994) suggested that few individuals actually achieve their 
true VO2max and that VO2peak values are frequently mistakenly reported as VO2max values. 
In a population of healthy individuals with good cardio-pulmonary function, the day-to-
day variation of intra-individual VO2max values has been reported to differ by 4% to 6% 
(Noonan & Dean, 2000). Furthermore, in populations with cardiopulmonary impairment, 
such as chronic obstructive pulmonary disease (COPD), the day-to-day intra-individual 
VO2max variation is described as differing by 6% to 10% (Noonan & Dean, 2000). 
Additional drawbacks or weaknesses in using ME tests are: i) if the subject isn’t able to 
achieve their VO2max without fatiguing first or succumbing to musculoskeletal 
complications, then the test results are invalid; ii) much higher levels of motivation are 
required by the subject; iii) they require additional and more sophisticated monitoring 
equipment, medically trained staff and are more laborious (Noonan & Dean, 2000).  
 
 As mentioned previously, SME tests use an indirect or predicted method of 
determining an individual’s VO2max. This predictive methodology is physically less 
demanding than ME tests, but its use introduces an additional source of error. Like any 
indirect method of measurement, SME testing relies on predictive equations to 
extrapolate from sub-maximally derived values in an attempt to predict maximal values 
(Jones, Eves, Haykowsky, Joy, & Douglas, 2008). The potential sources of error for this 
testing protocol include, but are not exclusive to: i) underestimation of VO2max with a very 
heavy work load due to greater relative increase in VO2 compared to HR; ii) failure to 
account for age in a mixed cohort of younger and older subjects, with the “within age 
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group” SD for maximal HR reported to be ± 10 bpm; iii) erroneous prediction of VO2 from 
workload due to a failure to account for varying mechanical efficiencies; and iv) 
erroneous prediction of VO2 from HR due to individual variation, potentially due to the 
training effect where well-trained individuals are usually overestimated and untrained 
individuals are usually underestimated (Cink & Thomas, 1981; Fleg et al., 2000; Legge & 
Banister, 1986; Patton et al., 1982).  
 
1.3.2.3 Exercise Test Selection 
 Although the reported incidence of adverse events are relatively low in both ME 
and SME, SME assessments are safer and a more tolerable means of CV evaluation. 
The choice of test should stem from the careful consideration of what parameters the 
study is trying to assess. The most appropriate exercise challenge tests should be as 
undemanding as possible yet strenuous enough to induce the CV adaptations desired 
and should have a normative performance index through which comparisons could be 
made. The current study involves the assessment of a population of, otherwise healthy, 
AYA cancer patients. We intend to track changes in their functional performance status 
over time. In a population with virtually no confounding comorbidities, typical functional 
assessments, like the 6-minute walk test, may not present enough of a challenge to 
discern changes in functional status. However, for patients in the midst of chemotherapy 
treatment protocols, ME testing may impose too high a demand on individual energy 
reserves and, in the long run, may discourage participation in the study (Noonan & 
Dean, 2000). These factors essentially limit the testing options to a SME protocol. 
 
 After much consideration, the modified Astrand-Rhyming cycle ergometry 
protocol emerged as the best fit for this project. This CV challenge has been used 
extensively in both epidemiological (Andersson, 2004; Siconolfi, Cullinane, Carleton, & 
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Thompson, 1982) and clinical studies (Hagberg, 1994; Hartung, Blancq, Lally, & Krock, 
1995). Furthermore, there were no reports of intolerance or serious adverse events (AE) 
when this protocol was used to test a similar population of AYA cancer patients (Thorsen 
et al., 2006; Thorsen et al., 2005). The test itself provides a performance outcome-based 
categorization through which performance trends can be established (Bailey, Shephard, 
Mirwald, & McBride, 1974) and has age- and sex-matched normative value sets to which 
our subjects can be compared (Bailey et al., 1974).  
 
 
1.4 Autonomic and Heart Function in Health and Disease: The Role of Exercise 
The inherent difficulty in defining the relationship between autonomic function 
and CV health lies in the limitations of assessment techniques. Investigations of human 
autonomic function rely on the non-invasive quantification of ANS-controlled effectors. In 
every case, aberrant findings may be attributable to either effector organ or ANS 
damage. Therefore, in the absence of pan-dysautonomia, the correct interpretation and 
characterization of subtle changes elicited by any single ANS challenge is impossible.  
 
Previous CVD-ANS research has attempted to define causal, predictive and 
prognostic relationships. Due to the aforementioned limitations with ANS testing, no 
definitive relationship has been established. However, therapeutic exercise training has 
been shown to improve common indices of CV and ANS function in multiple CVD 
populations. Given that cancer patients receiving chemotherapy are considered within 
the Stage A heart failure group (among the highest risk for developing CVD) (Bonow et 
al., 2005), engaging in regular exercise may have important protective benefits in this 
population. We acknowledge that it is impossible to discern whether the benefits 
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described in the following review are related to changes in either the CV effectors or the 
ANS’s control of. However, for the purposes of this review, common indices of CV and 
ANS function are referred to in the context with which they were presented (in the 
literature). Regardless of their relationship, the exercise-related improvements in these 
common indices preserve their importance. 
 
1.4.1 Introduction 
In recent years, evidence has emerged highlighting the potential influence of 
autonomic function in health, disease, as well as in the emerging role of therapeutic CV 
exercise to preserve and restore it. Drawing from important reviews articles, the 
following is a condensed review of the evidence supporting the use of exercise to restore 
autonomic function and, by doing so, improve or prevent associated CV morbidity and 
mortality (Rosenwinkel et al., 2001; Thayer & Lane, 2007).  
 
Inherent to our survival is the physiologic predisposition toward energy 
conservation (reflected in our resting circadian HR fluctuations and exercise-induced HR 
training adaptations). In health, dynamic modulation of energy expenditure is achieved 
through the synergistic influence of both ANS branches wherein parasympathetic 
influences dominate at rest. A common trait of pathology is the loss of this systemic 
compliance, and therein the capacity to adjust to dynamic metabolic needs and 
environmental stimuli. This systemic rigidity has been associated with morbidity and 
mortality (Lipsitz & Goldberger, 1992; Peng et al., 1994). Characterized by sympathetic 
dominance, either through vagal withdrawal or sympathetic hyperactivity, prolonged ANS 
imbalance has been ascribed to the development of a variety of chronic comorbidities 




1.4.2 Influence of Exercise on Healthy Autonomic and Heart Function 
Exercise studies, using both pharmacological blockade (SNS and PNS), HRV 
indices (PNS) and circulating catecholamine measurements (SNS), have played an 
important role in helping us understand the influence of both branches of the ANS in 
modulating our acute response to exercise.  
 
During exercise, the initial HR response (up to a HR of 100 beats per minute 
(bpm)) is primarily influenced by vagal withdrawal (Arai et al., 1989; Goldsmith, 1991; 
Robinson, Epstein, Beiser, & Braunwald, 1966; Rowell, 1993) with sympathetic 
modulation playing a larger role in moderate and heavy exercise adaptations 
(Christensen & Brandsborg, 1973; Orizio et al., 1988; Robinson et al., 1966; Rowell, 
1993). Conversely, following an acute bout of exercise, early HR recovery is thought to 
be largely influenced by parasympathetic reactivation with sympathetic withdrawal 
contributing more to later recovery (Imai et al., 1994; Ohuchi et al., 2000; Pierpont, 
Stolpman, & Gornick, 2000; Sears, Choate, & Paterson, 1998). 
 
Through a combination of intrinsic and systemic mechanisms, regular CV 
exercise has a profound and well-documented impact on decreasing resting and training 
HR and improving HR recovery from acute bouts of exercise. It is possible that ANS-
mediated pathways account for much of the systemic influence on these parameters. 
Studies investigating the impact of regular exercise training on resting HR and ANS 
function have identified that, compared to matched sedentary controls, resting 
parasympathetic activity levels are higher in endurance-trained athletes (Barney et al., 
1988; Dixon et al., 1992; Goldsmith et al., 1992a), middle-aged and older men (De 
Meersman, 1993; Seals & Chase, 1989) and physically active post-menopausal women 
(Davy, Miniclier, Taylor, Stevenson, & Seals, 1996). These finding have been 
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corroborated by longitudinal ANS-exercise studies of younger (De Meersman, 1992), 
middle-aged (Seals & Chase, 1989) and older individuals (Levy et al., 1998; Stein, 
Ehsani, Domitrovich, Kleiger, & Rottman, 1999). It has also been demonstrated that, at 
any given workload, trained individuals have reduced sympathetic activity (Hartley et al., 
1972; Lehmann, Schmid, & Keul, 1984). Finally, it is also well established that 
endurance-trained individuals recover faster from exercise than their untrained 
counterparts (Hagberg, Hickson, Ehsani, & Holloszy, 1980; Hagberg, Hickson, McLane, 
Ehsani, & Winder, 1979; Imai et al., 1994). 
 
1.4.3 Autonomic Dysfunction in Cardiovascular Disease 
Characterized by the aforementioned loss of dynamic autonomic control, 
pathologic perturbations of autonomic function have been shown to manifest in a variety 
of ways, including decreased HRV at rest (Dekker et al., 2000; Ziegler, Laude, Akila, & 
Elghozi, 2001), circadian HRV perturbations (Cygankiewicz, Krzysztof Wranicz, 
Bolinska, Zaslonka, & Zareba, 2004; Korpelainen, Sotaniemi, Huikuri, & Myllyla, 1997), 
high resting HR (Levy, 1990; Uijtdehaage & Thayer, 2000) and poor HR recovery from 
exercise (Shetler et al., 2001). Keeping in mind that these indices could either reflect 
effector organ or ANS dysfunction, as prognostic indicators, these clinical markers have 
all been strongly associated with increased risk of morbidity and mortality (Cole, 
Blackstone, Pashkow, Snader, & Lauer, 1999; Cole, Foody, Blackstone, & Lauer, 2000; 
Dekker et al., 2000; Ershler & Keller, 2000; Gibbons, 2002; Habib, 1999; Kiecolt-Glaser, 
McGuire, Robles, & Glaser, 2002; Nishime, Cole, Blackstone, Pashkow, & Lauer, 2000). 
 
1.4.4 Role of Exercise in Preserving or Restoring Autonomic Function 
As previously discussed, autonomic dysfunction may be associated with the 
greater risk of disease development, severity and mortality from a multitude of CV and 
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metabolic sequelae. Pharmacological studies of affected animals (Hull et al., 1994; 
Schwartz et al., 1988; Vanoli et al., 1991; Zuanetti, De Ferrari, Priori, & Schwartz, 1987) 
and large human trials (T. B. B. H. A. T. R. Group, 1982; T. N. M. S. Group, 1981; 
Hjalmarson et al., 1981; Packer et al., 1996) have demonstrated that the improvements 
in HRV (an important marker of autonomic and CV health) are associated with 
decreases the related morbidity and mortality risks. Similarly, human exercise training 
studies have clearly demonstrated exercise’s potential to improve HRV following 
myocardial infarction (La Rovere, Mortara, Sandrone, & Lombardi, 1992; Malfatto et al., 
1996; Malfatto et al., 1998; Oya, Itoh, Kato, Tanabe, & Murayama, 1999; Schwartz, La 
Rovere, & Vanoli, 1992), heart surgery (Iellamo, Legramante, Massaro, Raimondi, & 
Galante, 2000) and in those with congestive heart failure (Adamopoulos et al., 1995; 
Belardinelli, Georgiou, Cianci, & Purcaro, 1999; Coats et al., 1992; E. H. F. T. Group, 
1998; Keteyian et al., 1999; Kiilavuori, Naveri, Leinonen, & Harkonen, 1999; Kilavuori, 
Toivonen, Naveri, & Leinonen, 1995).  
 
In summary, pathologic perturbations to the ANS that disrupt its dynamic control 
mechanisms are associated with increased risk morbidity and mortality. Pharmacologic- 
and exercise-based interventions of affected individuals have been shown to improve 
prognostic and functional patient outcomes and decrease the associated morbidity and 
mortality risks. It may therefore be plausible that CV exercise training play a similar role 








1.5 Impact of Cancer on Autonomic and Cardiovascular Function 
 As in Section 1.4, we similarly acknowledge that the disease- and treatment-
related damage to the autonomic or CV systems, reported below, may be due to either 
effector organ or ANS dysfunction. 
 
1.5.1 Introduction 
 Relatively few studies have looked at the impact of cancer and chemotherapy on 
autonomic function. In the context of cancer rehabilitation, further investigation is 
warranted to help us understand the disease- and treatment-related impacts on CVRC. 
A review of the related literature reveals a number of mechanisms of autonomic and CV 
damage, which are likely to result in the impairment of patients’ CVRC and the potential 
for exercise-based therapeutic interventions. 
 
1.5.2 Impact of Cancer on Autonomic Function 
 Cancer has been shown to have direct and indirect effects on the NS (Falah, 
Schiff, & Burns, 2005). In their 2005 review, these authors identified a myriad of 
neuropathies (i.e. radiculopathies and plexopathies) resulting from the metastatic 
invasion of nervous tissue by malignant cells or from direct compression caused by the 
growth of an adjacent tumour. In either case, the severity of the symptoms and their 
functional relevance were associated with the locus and the overall size of the malignant 
growth (Falah et al., 2005). An indirect pathway of malignant NS damage stems from the 
development of paraneoplastic and paraproteinemic syndromes. These remote effects of 
cancer are not due to the primary tumour, metastatic disease, or treatment related 
abnormalities; rather, they are the result of an autoimmune response targeting a 
tumour’s neural antigens (Anderson, Cunningham, & Posner, 1987; Graus et al., 2004; 
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Levin, 1997; Pittock, Kryzer, & Lennon, 2004). Symptoms related to these syndromes 
often present as early as two years in prior to those related to the cancer itself 
(Anderson et al., 1987).  
 
Paraneoplastic syndromes most commonly occur in patients with small cell lung 
cancer, or cancers of the pancreas, testis, breast and gynaecological cancers (Rojas-
Marcos et al., 2003; Rudnicki & Dalmau, 2000). In an earlier investigation of autonomic 
function in twenty patients with lymphoma, baseline ANS evaluations demonstrated 80% 
of patients had subclinical ANS dysfunction, with 55% of patients experiencing persistent 
dysfunction post treatment (Turner, Boland, Parker, & Ewing, 1993). Consistent with the 
current literature (Darnell & Posner, 2003), the authors cited the probable influence of a 
paraneoplastic immune response as the cause of the baseline ANS dysfunction. 
Interestingly, despite the use of known neurotoxic chemotherapy agents, they reported 
significant improvements in ANS function post treatment (Turner et al., 1993). 
 
1.5.3 Impact of Cancer on Cardiovascular Function 
To the best of our knowledge, and with the exception of the previously described 
paraneoplastic influence, there are no published accounts of the impact of cancer on 
SME capacity, as indicated by SME testing, in any age group. Reason suggests that any 
malignancy, which directly compromises cardiac, lung, vascular, or neuromuscular 
functioning, may directly impact an individual’s physical work capacity. The severity of 
the complications associated with the growth of a tumour in any of the aforementioned 
locations would primarily depend on the extent of the local invasion. 
 
1.5.4 Chemotherapy: Mechanisms, Risks and Limitations 
Chemotherapy is aggressively used as a frontline defence against tumour 
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proliferation and metastasis in most cancer patients and is often used in concert with 
radiotherapy or surgical interventions. To provide increased efficacy, chemotherapeutic 
treatment strategies often include the synergistic use of multiple agents (drugs). These 
agents predictably differ in their mechanisms of action and are categorized into families 
based upon their pharmacodynamic mechanisms. Collectively, these agents disrupt 
cancer cell proliferation and metastases through the following pathways: i) anti-metabolic 
activity, ii) inhibition of DNA mediated transcription and replication, iii) inhibition of gene 
expression, iv) destruction of tumour cell DNA, v) inhibition of enzymatic function, vi) 
induction of apoptosis, vii) growth arrest, viii) disruption of membrane systems and trans-
membrane molecular transport and ix) the suppression of microtubule dynamics (Abal, 
Andreu, & Barasoain, 2003; Cepeda et al., 2007; Furlanut & Franceschi, 2003; 
Genestier, Paillot, Quemeneur, Izeradjene, & Revillard, 2000; Hande, 1998; Hideo, 
1970; Katzung, 1995; Longley, Harkin, & Johnston, 2003; Siegfried, Kennedy, Sartorelli, 
& Tritton, 1983). An inherent drawback to the use of chemotherapy is the non-cell and 
non-cell cycle specific nature of its effect. Once administered, these drugs act 
systemically and target both healthy and cancerous cells alike. Damage to healthy cells 
may manifest in several ways including nausea, vomiting, hair loss, cardiotoxicity, 
neuropathy and bone marrow suppression. Provided the affected cells have mitotic 
capabilities, the resulting damage may be temporary. However, there remain a multitude 
of problems and concerns surrounding the adverse side effects caused by these toxic 
interventions, including potentially life-threatening organ dysfunction and failure. 
Research has shown a distinct cumulative and dose-dependent symptom response 
associated with chemotoxicity (Doroshow, Locker, & Myers, 1980; Falah et al., 2005; 
Giantris, Abdurrahman, Hinkle, Asselin, & Lipshultz, 1998; Joshi et al., 2007; Minotti, 
Menna, Salvatorelli, Cairo, & Gianni, 2004). The incidence and severity of cardiotoxic 
and neurotoxic complications differ according to the agent used. See Appendix B and C 
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for a detailed overview of known cardiotoxic and neurotoxic agents, respectively. Among 
the host of affected organs and systems, the heart and its accompanying innervation are 
particularly susceptible to chemotherapy’s toxic effects (Aleman et al., 2007; Alter, 
Herzum, Soufi, Schaefer, & Maisch, 2006; Cardinale et al., 2006; Hirvonen, Salmi, 
Heinonen, Antila, & Välimäkiy, 1989; Jarfelt, Kujacic, Holmgren, Bjarnason, & Lannering, 
2007; Kosmas et al., 2008; Myrehaug et al., 2008; Tascilar, Loos, Seynaeve, Verweij, & 
Sleijfer, 2007; Viniegra et al., 1990; Zver, Zadnik, Černelč, & Koželj, 2008).  
 
1.5.5 Impact of Chemotherapy on Autonomic Function 
1.5.5.1 Chemotherapy-Induced Autonomic and Peripheral Neurotoxicity 
Of the many tissues susceptible to chemotherapy-induced damage, nervous 
tissue may be particularly vulnerable. Generally speaking, neurons are classified as 
post-mitotic tissue and, once mature, are no longer able to replicate themselves. This 
lack of reproductive capability is significant in that damage to this tissue type has been 
shown to cause chronic comorbidity, as previously described. Importantly, autonomic 
neuropathies typically involve damage to small, unmyelinated nerve fibers. Accordingly, 
chemotherapeutic agents known to damage these small fibers are the most likely disrupt 
ANS function. 
 
 In general, chemotherapy typically causes both large and small fibre 
neuropathies (Armstrong, Almadrones, & Gilbert, 2005) with autonomic neuropathies 
typically involving the latter (McLeod & Tuck, 1987). Autonomic neuropathies and 
impairments have been reported in cancer patients treated with a variety of 
chemotherapeutic agents, including: i) vincristine (Gomber, Dewan, & Chhonker, 2010; 
Legha, 1986), ii) cisplatin (Boogerd, Bokkel Huinink, Dalesio, Hoppenbrouwers, & 
Sande, 1990; Hansen, 1990), iii) paclitaxel (Ekholm, Rantanen, Antila, & Salminen, 
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1997; Ekholm et al., 2000), iv) gemcitabine (Dormann, Grunewald, Wigginghaus, & 
Huchzermeyer, 1998) and v) doxorubicin (DOX) (Hrushesky et al., 1991; Viniegra et al., 
1990). Furthermore, most of these compounds have been shown to accumulate in key 
autonomic regions, disrupt axon transport, interfere with microtubule assembly and 
function, cause demyelination and damage nervous support cells (Armstrong et al., 
2005; Quasthoff & Hartung, 2002). These chemotherapeutic agents are among the most 
commonly used in the treatment of AYA cancers.  
 
1.5.5.2 Autonomic Testing During and Post Chemotherapy 
The majority of autonomic evaluations completed thus far have assessed 
cardiovagal or adrenergic function utilizing the test battery described by Ewing and 
Clarke (Ewing & Clarke, 1986) with only one studying assessing sympathetic-mediated 
sweat function as described by Shahani (Shahani, Halperin, Boulu, & Cohen, 1984). 
 
Short term and circadian changes in HRV are known risk factors for CV disease 
(CVD) and all-cause mortality (Huikuri et al., 1994; Thayer & Lane, 2007). Using both 
RSA and 24-hour recordings, diminished HRV has been reported in patients treated with 
vincristine (Hirvonen et al., 1989), paclitaxel (Ekholm et al., 2000), DOX (Hrushesky et 
al., 1991), as well as patient groups treated with various combination therapies (Hansen, 
1990; Turner et al., 1993). Aberrant BP variability and maladaptive orthostatic responses 
have been observed in patients treated with paclitaxel, taxanes, vinca alkaloids and 
cisplatin (Ekholm et al., 1997; Jerian et al., 1993; Quasthoff & Hartung, 2002). The 
assessment of sympathetic-mediated sweat function found a prolongation of the skin 




Unfortunately, the methodology and reporting from these trials were inconsistent. 
Despite the frequent use of the protocol described by Ewing and Clarke, these studies 
lacked sufficient consistency in the selection and execution of their autonomic 
challenges, in the application of their eligibility and test criteria and many failed to include 
key methodological detail required to compare between trials. As such, there remains 
insufficient evidence to make any conclusions regarding the presence or nature of 
cancer-related autonomic dysfunction. 
 
1.5.6 Impact of Chemotherapy on Cardiovascular Function 
Stated previously, cancer patients receiving chemotherapy are considered within 
the Stage A heart failure group (among the highest risk for developing CVD) (Bonow et 
al., 2005). Despite improvements in screening techniques, drug administration and the 
use of cardio-protectant strategies, the introduction of new targeted anticancer drugs 
(also cardiotoxic), coupled with improved patient survival and an aging population 
increases the significance of cancer-related CV toxicity (Monsuez, Charniot, Vignat, & 
Artigou, 2010; Senkus & Jassem, 2011). The growing recognition and understanding of 
cancer-related CV toxicity has lead to a merging of medical disciplines, now referred to 
as cardio-oncology (Albini et al., 2010). Recent reviews on the subject have extensively 
covered the pathophysiologic mechanisms underlying the various drug-related CV 
toxicities (congestive heart failure, myocardial infarction, myocardial ischemia, 
hypotension, hypertension, arrhythmias, metabolic, and thrombotic complications) and 


















Rationale and Clinical Significance 
Despite therapeutic advances, cancer patients remain at risk of developing a 
host of disease- and treatment-related CV and metabolic morbidity, as compared to their 
peers. Emerging evidence in related fields has begun to establish links between the loss 
of dynamic autonomic control and risk/severity of CV sequelae and mortality. Regular 
CV exercise training has been shown to improve multiple prognostic and functional 
patient outcomes associated with autonomic and CV health, and, in doing so, may be 
effective in improving related outcomes for cancer patients. A relationship between 
cancer and CVD is evident. What is less clear is why cancer patients appear to be more 
susceptible to developing CVD. Multifactorial in nature, the development of these life-
altering conditions is likely influenced by complex interactions between behavioural, 
genetic, and environmental factors coupled with disease- and treatment-related damage 
to patients’ effector organs and systemic physiology. 
 
One possible explanation for the cancer-related increase in CVD development 
risk may be the effect of cancer and anticancer therapy on ANS function. This 
relationship is well supported in the literature but has yet to be clearly defined. The ideal 
launch point for this investigation requires study within the AYA cancer population for 
two reasons. First, ANS function is easily perturbed, known to decline with age and be 
influenced by existing comorbidities. AYA cancer patients, however, are the most likely 
to have good ANS reflexes as they are young and relatively unaffected by comorbidities. 
Second, in comparison with older cancer patients, the premature development of CVD in 
AYA cancer survivors affects many more years of life per individual. The implication of 
this carries significant personal and societal burden. 
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The general aim of this study was to establish the feasibility of testing autonomic 
and CV function in AYA cancer patients undergoing treatment for cancer by: i) defining 
the methodological pitfalls and best-practice criteria for ANS testing in cancer, and ii) 
providing initial physiologic evidence of autonomic perturbations in cancer patients using 
the CASS. As previously mentioned, ANS function may be perturbed by cancer and 
anticancer therapies. However, given the heterogeneity of the population (Dx and 
treatments) and the complexity of the reflex responses, ANS testing during cancer 
treatment may not provide reliable evidence of ANS function. Accordingly, the 
significance of this study is to define key methodological parameters required to study 
ANS function in patients undergoing a variety of chemotherapy protocols, for the 
purposes of launching future investigations. If successful, we intend to continue this line 
of investigation in an effort to verify the occurrence of cancer-related ANS damage, and, 
if warranted, track the pathogenesis of these complications in an effort to define the 




















Research Objectives and Hypotheses 
The purpose of this study was to assess the feasibility of conducting concurrent 
ANS and CV evaluations in AYA cancer patients undergoing treatment for various 
cancers. Our objectives were to i) identify the methodological pitfalls of autonomic 
testing in cancer, ii) define best-practice criteria for the future testing of autonomic 
function in cancer, and iii) provide initial physiologic evidence of autonomic perturbations 
in cancer patients using the CASS. In keeping with recent pilot study design and 
reporting guidelines (Thabane et al., 2010), we crafted this research project to reflect the 
requirements of a similar, larger scale investigation. 
 
Our primary research question was: Does cancer or chemotherapy have a 
significant impact on autonomic nervous function in AYA cancer patients at rest? Our 
primary research hypothesis was that, AYA cancer patients would demonstrate a 
significant decrease in ANS function (as indicated by the CASS) after receiving 
chemotherapy. 
 
Our secondary research question was: If identified, does cancer or 
chemotherapy-related autonomic dysfunction impair exercise tolerance of AYA cancer 
patients to, in, and in recovery from a brief SME challenge? Our secondary research 
hypothesis was: If present, chemotherapy-related autonomic dysfunction would 
significantly impair the exercise response of AYA cancer patients to, and in recovery 






















Chapter IV  
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Assessing the Impact of Cancer and Chemotherapy on Autonomic Function and 




Despite therapeutic advances, cancer survivors remain at risk of developing a 
host of disease- and treatment-related cardiovascular (CV) and metabolic morbidities 
(Albini et al., 2010; Demark-Wahnefried et al., 2005; Monsuez et al., 2010; Oeffinger et 
al., 2010; Senkus & Jassem, 2011). Emerging evidence in related fields has begun to 
establish links between autonomic nervous system (ANS) impairment (as evidenced by 
short term and circadian changes in heart rate (HR) variability (V)) and increased 
risk/severity of CV disease (D) and all-cause mortality (Cole et al., 1999; Cole et al., 
2000; Dekker et al., 2000; Ershler & Keller, 2000; Gibbons, 2002; Huikuri et al., 1994; 
Kiecolt-Glaser et al., 2002; Nishime et al., 2000; Thayer & Lane, 2007). Using both short 
duration and 24-hour recordings, diminished HRV has been reported in patients treated 
with vincristine (Hirvonen et al., 1989), paclitaxel (Ekholm et al., 2000), DOX (Hrushesky 
et al., 1991), as well as patient groups treated with various combination therapies 
(Hansen, 1990; Turner et al., 1993). Aberrant blood pressure (BP) variability and 
maladaptive orthostatic responses have been observed in patients treated with 
paclitaxel, taxanes, vinca alkaloids and cisplatin (Ekholm et al., 1997; Jerian et al., 1993; 
Quasthoff & Hartung, 2002). The only assessment of sympathetically-mediated sweat 
responses identified a prolongation of the response latency at both the hand and foot 
(Argyriou et al., 2005). Unfortunately, the methodology and reporting from these trials 
were inconsistent. Despite the frequent use of the protocol described by Ewing and 
Clarke, these studies lacked sufficient consistency in the selection and execution of their 
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autonomic challenges, in the application of their eligibility and test criteria and many 
failed to include key methodological detail required to compare between trials. As such, 
there remains insufficient evidence to make any conclusions regarding the presence or 
nature of cancer-related autonomic dysfunction. 
 
Interestingly, regular CV exercise training has been shown to improve HRV (an 
important marker of autonomic and CV health) in various CVD populations 
(Adamopoulos et al., 1995; Belardinelli et al., 1999; Coats et al., 1992; E. H. F. T. Group, 
1998; Iellamo et al., 2000; Keteyian et al., 1999; Kiilavuori et al., 1999; Kilavuori et al., 
1995; La Rovere et al., 1992; Malfatto et al., 1996; Malfatto et al., 1998; Oya et al., 1999; 
Schwartz et al., 1992). As such, this type of therapeutic exercise may be effective in 
improving similar CV outcomes in cancer patients. A relationship between cancer and 
the development of CVD is evident. What is less clear is why cancer patients appear to 
be more susceptible to developing CVD. This quandary is unquestionably multifactorial 
in nature. The development of these life-altering conditions is likely influenced by 
complex interactions between behavioural, genetic, and environmental factors coupled 
with disease- and treatment-related damage to patients’ effector organs and systemic 
physiology.  
 
One possible explanation for the cancer-related increase in CVD development 
risk may be the effect of cancer and anticancer therapy on ANS function. This 
relationship is often suggested in the literature but has yet to be clearly defined. The 
ideal launch point for this investigation requires study within the adolescent and young 
adult (AYA) cancer population for two reasons. First, ANS function is known to decline 
with age and is influenced by existing comorbidities (Low, 1997). By virtue of their age, 
AYA cancer patients are the most likely to have normal ANS reflexes as they are young 
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and relatively unaffected by comorbidities. Second, in comparison with older cancer 
patients, given their average 5-year survival rates and greater number of years of life 
ahead of them (Canada, 2012; Ontario, 2006), the premature development of CVD in 
AYA cancer survivors is likely to account for many more years of life affected per 
individual. The implication of which carries a tremendous potential burden both to society 
and thousands of AYAs across Canada. 
 
The purpose of this study was to assess the feasibility of conducting concurrent 
ANS and CV evaluations in AYA cancer patients undergoing treatment for various 
cancers. As previously mentioned, ANS function may be perturbed by cancer and 
anticancer therapies. However, given the heterogeneity of the population (diagnoses and 
treatments) and the complexity of the reflex responses, ANS testing during cancer 
treatment may not provide reliable evidence of ANS function. Our additional feasibility 
concerns included: i) recruitment potential (given that AYAs account for only 10% of 
cancer diagnoses, and we recruited at time of diagnosis (Dx)), ii) retention rates 
(anticipated difficulty with compliance and follow-up), iii) capacity to establish a baseline 
(T1) assessment (variable time between initial Dx and commencement of systemic 
therapy), iv) performance and tolerability of the ANS and CV test battery components 
and v) the confounding effects of common symptom-management medications. 
 
Our objectives were to identify the methodological pitfalls of autonomic testing in 
cancer, define best-practice criteria for the future testing of autonomic function in cancer 
and, through the use of modern techniques, provide physiologic evidence of autonomic 
perturbations in AYA cancer patients as a potential precursor to the development of 
CVD. Accordingly, our research questions and methodology were designed to reflect 
those to be used in a subsequent, larger investigation of the subject. 
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Our primary research question was, does cancer or chemotherapy have a 
significant impact on autonomic nervous function in AYA cancer patients at rest? Our 
primary research hypothesis was that, AYA cancer patients would demonstrate a 
significant decrease in ANS function (as indicated by the composite autonomic scoring 
scale (CASS)) after receiving chemotherapy (Low, 1993b). Our secondary research 
question was, if identified, does cancer or chemotherapy-related autonomic dysfunction 
impair exercise tolerance of AYA cancer patients to, and in recovery from, a brief sub-
maximal exercise (SME) challenge? Our related hypothesis was, if present, 
chemotherapy-related autonomic dysfunction would significantly impair the exercise 
response of AYA cancer patients to, and in recovery from, a brief SME challenge.  
 
Methods 
Participants and Setting 
 We aimed to recruit twenty patients and twenty control subjects matched for sex 
and age. Initially based on common chemotherapeutic agents within their treatment 
protocols, patients with newly diagnosed sarcomas, genito-urinary (testicular and 
ovarian) and gastro-intestinal cancer patients (aged 18-45) were recruited from the AYA 
Oncology Program of the Jewish General Hospital (JGH), Montreal Quebec. Patients 
with all stages of disease were eligible provided they had a performance status (ECOG) 
≤ 2. Exclusion criteria: i) use of any medications, at T1, that interfered with autonomic or 
CV function, ii) intrinsic cardiac disease or ANS-perturbing comorbidity (e.g., arrhythmia, 
intraventricular conduction defects, evidence of cardiac ischemia, pre-existing 
cardiomyopathy, diabetes, hypertension, neuropathy, seizure disorder) and iii) an 
inability to perform any of the T1 ANS or CV challenges due to tumour location. In 
accordance with our feasibility objectives, detailed records of recruitment, retention, 
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testing and confounding drug use were kept. Institutional review boards at both the 
Jewish General Hospital and Concordia University approved this study. 
 
Study Design and Procedure 
Subject recruitment took place at the weekly AYA Oncology Program clinic, as well 
as various other, JGH-based, Segal Cancer Centre oncology clinics. Following an initial 
appropriate Dx, the investigator obtained medical clearance from the oncologist and then 
the patient’s consent to explain the study. Patients were then given a copy of the 
informed consent for review and a chance to ask questions. For those agreeing to 
continue, detailed pre-test instructions were given according to best practices of ANS 
and CV testing (Jones et al., 2008; Low, 1997). T1 was booked within 24 hours of 
recruitment. Informed consent was signed at the T1 assessment and in the presence of 
no less than two study investigators. All patients underwent ANS and CV evaluations at 
T1 (post Dx and pre-chemotherapy) and follow up ((T2) - between the 4th and 5th 
chemotherapy treatments).  
 
All procedures were conducted in the Autonomic Reflex Laboratory at the JGH. 
The non-invasive battery of tests used at rest (respiratory sinus arrhythmia (RSA), 
Valsalva maneuver (VM), tilt-table and the quantitative sudomotor axon reflex test 
(QSART)) provided information concerning cardiovagal, sympathetic adrenergic 
vasomotor and cardiomotor, as well as postganglionic sympathetic cholinergic 
sudomotor function. The severity and localization of the type and sites of autonomic 
dysfunction was accurately graded and compared using a validated CASS (Low, 1993a, 
1993b). These tests have been routinely performed under clinical and clinical research 
conditions in patients who were considered to be significantly disabled by diabetes, 
orthostatic intolerance, chronic fatigue syndrome (Schondorf, Benoit, Wein, & Phaneuf, 
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1999), or Alzheimer’s disease (Schondorf, Benoit, & Chertkow, 2000) in the Autonomic 
Reflex Laboratory of the JGH for the last 20 years. Immediately following the resting 
ANS protocol, the subjects were transferred to an adjacent evaluation room to perform a 
brief, 6-min, SME challenge on a cycle ergometer (Astrand & Ryhming, 1954). The 
exercise test was proposed to obtain a functional assessment of the indices of CV 
function (e.g., central (e.g., HRV, HR, stroke volume and cardiac output (CO)) and 
peripheral (BP and systemic vascular resistance)) that correlate with the ANS testing. 




Per-Visit Assessments  
 
 
     ‘Per-Visit Timeline’ includes ‘Time Per-Test’ and ‘Instrumentation/De-Instrumentation Time’. 
 
Figure 13: Sequence of tests 
 
Pre-Test Data Collection 
Before each assessment, subject height, weight and current medications were 
recorded. Subjects also completed the Brief Fatigue Inventory (BFI) and weekly physical 
activity (PA) METhrsweek-1 reports.  
 
Autonomic Testing 
Cardiovagal and Adrenergic Assessments 
HR, finger arterial pressure, end tidal CO2 were continuously recorded for all 
cardiovagal and adrenergic autonomic challenges. The measurement devices were 
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applied pre-test, disconnected during transfer and reconnected. HR was derived from 
the R-R interval of the surface EKG (EKG 101 Patient monitor; Biomedical Systems Inc.; 
St. Louis, MO), finger arterial pressure measured with a volume clamp 
photoplethysmograph (Finometer MIDI Model 2 – b1.0; Finapres; Amsterdam, NL), and 
end tidal CO2 via nasal prongs (Oximax N-85; Nelicor; St. Louis, MO) (Halliwill et al., 
1997; Whitney, 1953). Cardiac output (CO) was derived from the finger arterial pressure 
waveform using the pulse contour method (Jellema, Imholz, van Goudoever, Wesseling, 
& van Lieshout, 1996). These continuous non-invasive measures of CO were able to 
accurately track relative changes in CO but did not provide accurate measures of actual 
CO. All analog signals were appropriately sampled at 400 Hz by a computer equipped 
with an eight-channel A/D acquisition card and software (WindaqPRO; Dataq; Akron, 
OH). 
 
 The ANS assessment protocol began with measuring the aforementioned 
responses for 10 minutes of supine rest followed by 10 minutes of head-up tilt at 80o. 
The patient was then returned to the supine position. Subsequently the HR response to 
deep breathing at 6 breaths / min for 10-12 respiratory cycles was measured (Schondorf 
et al., 1999). The patient then performed two VMs while supine. To perform this 
manoeuvre the patient blew into a tube and attempted to push a column of mercury to 
40 mmHg and maintain that effort for 15 sec (Low, 1993b; Schondorf et al., 1999).  
 
Sudomotor Assessment 
The standard test protocol of sudomotor function (sweat gland activity) uses the 
QSART as a specific measure of postganglionic cholinergic sympathetic sudomotor 
function (Low, Caskey, Tuck, Fealey, & Dyck, 1983; Low & Opfer-Gehrking, 1992; Low, 
Opfer-Gehrking, Proper, & Zimmerman, 1990). Measurements were made while the 
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patient was supine from 4 small multi-compartment sweat cells placed at standard sites 
(distal forearm, proximal leg, distal leg and foot). Sweating was provoked by 5 minute 
iontophoresis of 10% acetylcholine (Iontonphor II Model 6111PM/DX; Life-Tech Inc.; 
Burlington, ON). Sweating was recorded for 10 min and expressed as μl/min/cm2 
(QSWEAT; WR Medical Electronics Company; Maplewood, MN). During iontophoresis, 
the patient may experience a tingling or prickling sensation, which was not painful. 
 
Exercise Testing 
A brief (6-min) SME test on a bicycle ergometer (Ergomedic 828E; Monark; 
Uppsala, SE) was then performed, using a standardized protocol (Astrand & Ryhming, 
1954). After comfortably positioning each subject on the ergometer, HR and BP 
responses were measured during a 3 min warm-up (no resistance) and work phases 
(consisted of pedaling against a self-determined, constant load at 50 revolutions / min for 
6-7 minutes (HR adaptation-depending)). Rate of perceived exertion (RPE) was 
collected between the 2nd last and last minute of each work phase. Following this work 
phase, subjects remained seated upright on the bicycle and continued to pedal (50 
revolutions / min with no resistance) for an additional 4 min to ensure a safe and 
uneventful recovery. Subjects were monitored minute-by-minute and data was recorded 
(using the aforementioned CV assessment instrumentation) continuously throughout the 
entire protocol. The workload was selected to elicit heart rates between 120-150 
beats/min. This intensity is considered to be light to moderate based upon projected 
maximal HR reserve values for a population between 18-45 years. This protocol has 
been followed before without any adverse effects in cancer patients who had recently 





 Accordingly, and in the absence of best-practice guidelines for ANS testing in 
cancer, we based most decisions for our feasibility criteria (FC) on the combined results 
of recent, in-treatment, randomized controlled exercise trials in cancer (Adamsen et al., 
2009; Courneya et al., 2007; Courneya et al., 2009; Mock et al., 2005) and McGill AYA 
Oncology Program clinic data (Palumbo & Kavan, 2008). The relevant feasibility 
endpoints for these trials are summarized in Table 4. In attempting to establish our FC, 
several important factors impacted our decision-making. Previous investigations of ANS 
function in cancer (Argyriou et al., 2005; Boogerd et al., 1990; Ekholm et al., 1997; 
Ekholm et al., 2000; Fagundes et al., 2011; Hansen, 1990; Hirvonen et al., 1989; Jerian 
et al., 1993; Roca et al., 1985; Turner et al., 1993; Viniegra et al., 1990) often had small 
sample sizes, did not establish pre-treatment baselines, included a wide age-range of 
participants and lacked sufficient and consistent methodological and results reporting. 
As such, we had to draw important feasibility information from related, exercise oncology 
literature. The reviewed exercise oncology trials included comprehensive reports of key 
methodology, recruitment, trial design and participant flow and, therefore, was often 
more useful in helping define our FC. The reported averages from these trials (Table 4) 
were combined and listed in Table 5. In accordance with Thabane et al. (2010), we 
established FC that, given that our study did not include an intervention, were more 
stringent than evidenced in the aforementioned intervention and observation trials 






Table 4: Relevant Feasibility Endpoints (Exercise Oncology) 
 
* estimated based on reported recruitment period of 1998 & 2001 
** details of baseline medical exemptions provided for 2 of 4 studies 










1. Recruitment & Access 
   1.i: T1 CV or NS Morbidity & Medication Use 







2. Patient Retention Rate(based on willingness and ability  
to participate and completion of T2 assessment) 
91.8% > 95% 
3. Pre-Chemo Baseline 
   3.i: Number days between Dx& T1 
 
   3.ii: < 20% subjects missed on the basis of time- 
related constraints (ie. start of treatment or lab availability) 
 












< 20%  
4. Test Performance & Tolerability 
   4.i: Completion of all test components 
   4.ii: Incidence of AE &AC 
 
93.9% 
0.67% AE & NR AC 
 
> 95% 
< 1% AE &<10% AC 
5. PCM Use 
(cancer-related symptom management) 
NR Reviewed post-study 








Mock et al.,   
2005 
 Recruitment Period (months) 36 30 36 36* 
 # of Hospitals Involved 2 3 1 4 
 # Patients Assessed 953 1,468 1,306 234 
 Ineligible 237 732 620 47 
 Medical Exclusion  
(non-cancer related) 
77 76 NR NR 
 Declined Participation 447 494 564 66 
 # Patients Eligible 269 242 122 121 
 # Patients Tested @ T1 269 242 122 119 
 # Patients Retested 235 225 117 108 
 % Patient Retention 87.4% 93.0% 96.0% 90.8% 
 # AEs 0 2 3 0 




Severity of autonomic dysfunction was assessed using the CASS (Low, 1993b) 
using commonly measured indices of CV autonomic function (HR and BP). Spectral 
analysis of HR and BP variability both at rest and during head-up tilt (Novak, Novak, 
deMarchie, & Schondorf, 1995; Novak, Novak, & Schondorf, 1993; Schondorf, 1993) 
provided additional indices of the integrity of cardiac autonomic and sympathetic 
vasomotor innervation as well as a measure of baroreflex modulation of HR (Hughson, 
Quintin, Annat, Yamamoto, & Gharib, 1993; Schondorf, 1993). Other indices of 
baroreflex modulation were obtained from analysis of the cardiomotor response to the 
VM (Kautzner, Hartikainen, Camm, & Malik, 1996) and from the sequence method 
described by Blaber, Yamamoto, & Hughson (1995). T1 comparisons were made using 
standard t-tests. A 2x2 repeated measures ANOVA was performed on all self-report and 
objective measures of ANS and CV function. Based on recent pilot study methodological 
recommendations, given the feasibility-nature of this investigation, a power analysis was 




Study recruitment took place from March 2010 to July 2011 (see Figure 14 for 
summary). A total of fourteen cancer patients and thirteen sex-and age-matched controls 
were tested at T1. Subject demographic information is presented in Tables 6 & 7 (data 
only provided for retained subjects completing both T1 and T2 assessments). The 
patient group consisted of a variety of diagnoses and stages of disease. Of these, twelve 
patients and eleven controls completed the second test. Study groups were closely 
matched in gender, age and body mass index (BMI). There was a significant difference 
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at T1 in weekly PA levels (METhrsweek-1) between the patient (M=7.5 METhrsweek-1, 
SD=7.6) and control (M=26.3 METhrsweek-1, SD=22.9) groups; t(21)=2.594, p = 0.017. 
There was also a trend toward a significance difference in T1 BFI scores (patient 
(M=27.3, SD=14.2) and control (M=15.5, SD=13.2); t(21)=2.066, p = 0.051). No member 
of either group displayed evidence of severe ANS or CV dysfunction at either testing 
time point. 
 
Table 6: Subject Characteristics (T1) 
 
 Patient Control 
n 12 11 
Sex (women) 67% (n=8) 55% (n=6) 
Age (years) 35.0 ± 8.9 33.8 ± 8.1 
Weight (kg) 66.5 ± 11.5 66.3 ± 12.5 
BMI (kgm-2) 23.0 ± 3.5 23.0 ± 2.1 
BFI 27.3 ± 14.2 15.5 ± 13.2** 
PA level, METhrsweek-1 7.5 ± 7.6 26.3 ± 22.9 * 
Predicted^* VO2max Lmin
-1 2.54 ± 0.70 3.29 ± 0.97** 
* indicates significance ≤ 0.05 
** indicates trend toward significance BFI p=0.051 & VO2 p=0.058 




Table 7: Patient Demographics 
 
Patient Diagnoses and Treatments: 
 
 Breast (n=5): 4 cycles FEC + Paclitaxel (n=1); 4 cycles AC (n=4) 
 Gastrointestinal 
   - Pancreatic (n=1): Folforinox x 3 + Gemcitabine x 1 
   - Colon (n=1): Xelox x 4 
   - Anal (n=1): Mitomycin C + 5 FU x 4 
 Hematological 
   - Hodgkin’s Lymphoma (n=2): ABVD 
   - Non-Hodgkin’s Lymphoma (n=1): R-CHOP 
 Other 
   - Adenocarcinoma (unknown origin) (n=1): C-Pacli 
   - Parotid (acinic cell carcinoma) (n=1): C-Pacli 
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Staging at Diagnosis (I-IV): 
 
   I – 1 
   II – 6 
   III – 3 
   IV – 3 
Performance Status (0-4): 
T1 
  ECOG 0: 3 
  ECOG 1: 8 
  ECOG 2: 2 
T2 
  ECOG 0: 4 
  ECOG 1: 7 
  ECOG 2: 1 
BMI: 
T1 
  23.3 
T2 







* data not included in analysis 
 






We assessed the aforementioned feasibility concerns using the criteria in Table 
5. In our opinion, and if successful, the achievement of these FC would suggest that the 
investigation of ANS function in cancer would be reproducible on a larger scale. 
 
Criteria I: Patient Recruitment and Access (Table 8; Figures 15 and 16) 
 Over the course of the first 39 weeks of recruitment, due to stagnant recruitment 
rates, we amended our inclusion criteria three times to include recruitment from outside 
the AYA Oncology Program clinic, of patients having all tumour types (still excluding 
those directly involving the central and peripheral NSs and any effector organs of the CV 
system (heart, lungs, and vasculature)) and of patients up to 45 years (previously 39 
years). As such, our recruitment reporting has been divided into two phases. Phase I 
includes the first 39 weeks of recruitment. Phase II includes the 26 subsequent weeks 
where no additional protocol amendments were made. Refer to Figure 16 for an 
overview of patient diagnoses by recruitment phase. 
 
Sub-Criteria I.i: Comorbidity and Medication Free 
 Of the twenty-eight otherwise eligible patients (OEP), only one person presented 
at T1 with previous CV or NS morbidity and use of related medication (details: sinus 
arrhythmia, high BP and related medication use). This accounts for a 3.6% incidence of 
the tested criteria, and therefore fits our established cut off of < 5%. Furthermore, and 
excluding the central and peripheral NS patients (n=16), the incidence of T1 CV 






Criteria 1: Recruitment & Access 
 
 
Table 8: Patient Recruitment & Access 
 





TOTAL PATIENTS APPROACHED 
 
54 (57.5% of total) 40 (42.5% of total) 
TOTAL ELIGIBLE PATIENTS 







TOTAL INELIGIBLE PATIENTS  
 Ineligible Dx 
 Recurrent disease/not chemo-naïve 
 No therapy/refuse therapy 
 Age restricted 
 No cancer/information 

















CRITERIA 1.i   
 < 5% exclusion based on T1 presence of CV/NS 
morbidity or use of PCMs 
 




FC 1.i was 100% achieved. 
 
Total Eligible Patients Identified 
 Weeks per phase 















FC 1.ii was 100% achieved.  
 
Percentages reflect phase totals, unless otherwise stated. 
^ based on eligibility criteria at the time 
 
Sub-Criteria I.ii: Patient Identification (Figure 16) 
 Phase I subject identification was difficult, with only 7.4% of patients screened 
meeting our eligibility criteria (see Figure 16 for summary of patient eligibility by phase). 
However, after having modified our inclusion criteria, Phase II patient identification rates 
were much better. Based on an identification average of 57.6% or 0.885 eligible 
patients/week, and extrapolating this 26-week experience over 52 weeks, our projected 
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identification rate was approximately 46 potential subjects/year. With our patient 
identification FC defined as ≥ 40 patients/year, and drawing from our Phase II 
experience, we feel that the projected identification rate of 46 patients/year lends itself to 
achieving adequate trial recruitment, especially if coupled with adequate infrastructure 
support. More specifically, due to the fact that the primary recruiter was also responsible 





Figure 15: Overview of patient diagnoses by phase 
 
Criteria 2: Subject Retention (Table 9) 
 We were successful in recruiting 19 patients for our study, with 14 completing T1. 
Three of the five untested patients initially agreed to participate but withdrew their 
consent once the reality of their Dx set in. Two from this group cited personal crisis and 
the third cited family crisis as their reasons for withdrawing consent. When followed-up 
with, the remaining two simply stated they had forgotten (at which point they had both 
begun treatment). The latter two incidence pointed out a methodological weakness in 





Figure 16: Patient eligibility by phase 
 
telephone reminders the day before evaluations. During the routine phone booking of T2 
assessments, one patient requested to discontinue participation. The reason for which 
was described as ‘having too much on [their] plate’ and nothing to do with the tolerability 
of the test battery. A second patient was dropped from study when we learned that they 
had an unreported previous history of cancer and related therapy (T1 data was dropped 
from analysis). In summary, of the 13 patients eligible to complete T2, 12 (92.3%) 
returned for testing; which fell just short of our FC of > 95% retention rate. It should be 
noted, however, that our retention rate of 92.3% was comparable to those reported in 
















Criteria 2: Retention 
 
 
Table 9: Patient Retention Rates 
 
 Subject Retention 
 
T1 EVALUATION (T1) 
 Total recruited 
 Completed T1 
 Dropped from study  
(failure to report previous use of potentially cardiotoxic therapy) 











IN-TREATMENT EVALUATION (T2) 
 Total eligible for T2 
 Total completed T2 







CRITERIA 2  
 > 95% retention rate (based on willingness and ability to 







FC #2 was 97.2% achieved. 
 
 
Criteria 3: Baseline Establishment (Table 10) 
 AYA Oncology Program clinic data indicated that, although 15.7% of new 
patients beginning treatment on the day of their first visit, there was a window of 
opportunity to collect our T1 measurements. According to these data, (Palumbo & 
Kavan, 2008) approximately 50% of patients began treatment within two weeks of Dx 
and an additional near 17% within a third week (not including the aforementioned 
15.7%). Despite having upwards of 2-3 weeks to collect T1 data, considering the 
inevitable personal crisis following many cancer diagnoses, we were concerned that 
many AYAs may not prioritize participation. Further compromising our T1 collection 
capacity was the availability of the testing lab, whose primary function being clinical 




Criteria 3: Pre-Chemo Baseline 
 
 
Table 10: T1 Testing Opportunity 
 
 T1 Testing Opportunity 
 
Patient Recruitment Flow 
 Avg. # days between Dx& recruitment 
 Avg. # days between recruitment & T1 assessment 









 ≤ 9 days between Dx and T1 evaluation 
 





FC #3.i was 99.9% achieved. 
 
Time Related Exclusions 
 Total OEP 
 # Recruited 
 # treatment conflict 
 # Investigator conflict 










 < 20% subjects missed on the basis of time-related 
constraints (i.e. start of treatment, lab availability) Time-Related Conflicts 
FINDING FC #3.ii was 91% achieved. 
 
 
Sub-Criteria 3.i: Days Between Dx and T1 
 McGill AYA Oncology Program data suggested that 67% of patients began 
treatment between 1 – 18 days following their Dx. Whenever necessary, we attempted to 
book all T1 assessments as quickly as possible. With an average of 9.1 days (SD=6.2) 
between Dx and T1, our results slightly exceeded our FC. However, two of our patients 
had > 6 weeks between initial Dx and commencement of treatment. As such, we did not 





Sub-Criteria 3.ii: Time-Related Testing Constraints 
We sought to not miss recruitment of > 20% of OEP on the basis of time-related 
constraints. Of the 26 OEP, 19.2% of patients began treatment too soon to collect our T1 
data. Despite making every effort to accommodate, an additional 7.7% of patients were 
lost to lack of lab availability. Overall, we had to exclude 26.9% of OEP on the basis of a 
time constraint, extending just beyond our 20% FC cut off.  
 
Criteria 4: Test Performance and Tolerability (Table 11) 
Sub-Criteria 4.i: Test Performance 
 At T1 evaluation, two patients presented moderately symptomatic (discomfort 
and pain related to tumour location). Without these symptoms, according to our eligibility 
criteria, the tumour locations would not have prevented testing. In each case, we 
decided to proceed with a modified testing protocol. At T1, Patient 1 completed all but 
the exercise component, and Patient 2 completed all but the VM and exercise 
components. At T2, Patient 1 (experiencing a prolapsing ostomy) and Patient 2 both 
completed all but the VM and exercise components.  
 
Combining both trials for each group, the patient group completed 114 of 121 
(94.3%) possible trials (including the two previously described patients); whereas, the 
control group completed 113 of 115 (98.3%) of possible trials. Comparing just the 
attempted trials in each group, only 2.6% of trials were stopped in the patient group vs. 
1.7% of trials in the control group. Overall, with an established FC cut off of > 95% 
completion rate of all tests, the patient group average completion rate was (94.3%) and 





Sub-Criteria 4.ii: Testing Tolerance 
 This ANS test battery (Tilt, RSA, VM and QSART) has been used to test an array 
of patient groups (Low et al., 2004; Schondorf et al., 2000; Schondorf et al., 1999). 
Although we expected differences in performance outcomes, we did not anticipate 
differences in test ability or tolerance between groups. We assessed the testing 
tolerance by tracking the incidence of AC and AE. Standard of care in the delivery of 
these evaluations requires that evaluators ‘check-in’ with participants following each test. 
As such, general comments and complaints were regularly recorded. With respect to our 
criteria, AC was defined as a person voicing a concern about discomfort or evoked 
symptoms (without being prompted) or repeating previously expressed concerns beyond 
the initial check-in.  
 
ACs were recorded in 6 of 117 (5.1%) attempted trials for the patient group and 
in 3 of 115 (2.6%) attempted trials in controls. There was 1 AE in 117 (0.85%) patient 
trials and no AE in controls. The AE took place during a T2 QSART test. In this case, the 
patient reported an unusually high level of discomfort during stimulation (recorded AC). 
When investigated further, the electrode used at that location appeared faulty. The lab 
supervisor was immediately called and cleared the patient to proceed with testing after 
assessing the mild skin irritation. Combining the incidence of the aforementioned factors 
(6 AC and 1 AE), overall evidence of testing intolerance was recorded in 5.1% of patient 
trials. In controls, intolerance was recorded in a total 3.5% of trials. Overall, we achieved 
our FC of < 1% incidence of AE (actual incidence 0.85%) and < 10% incidence of AC 






Criteria 4: Autonomic and Cardiovascular Testing Capacity and Tolerability 
 
 
Table 11: Patient Testing Performance and Tolerability 
 
 Patients Controls 
Tilt Table 
 Total possible trials 
 Total trials not attempted 
 Total trials stopped 
Self-Report Complaints & Comments 
 AC 

















 Total trials completed 
 Total trials not attempted 
 Total trials stopped 
Self-Report Complaints & Comments 
 AC 



















 Total possible trials 
 Total trials not attempted 
 Total trials stopped 
Self-Report Complaints & Comments 
 AC 


















 Total possible trials 
 Total trials not attempted 
 Total trials stopped 
Self-Report Complaints & Comments 
 AC 
















Astrand-Rhyming – Cycle Ergometer 
 Total possible trials 
 Total trials not attempted 
 Total trials stopped 
Self-Report Complaints & Comments 
 AC 


























FC #4.i was 99.3% achieved. 
 
CRITERIA 4.ii 
 < 1% incidence of AEs  
 < 10% incidence of AC TEST TOLERABILITY 
FINDING FC #4.ii was 100% achieved. 
* virtually every subject (patient & control) mentioned varying degrees of discomfort 





Criteria 5: Potentially Confounding Medication Use (Figures 17 and 18) 
 The consideration and impact of common symptom management medication on 
physiologic patient outcomes has not been well reported in behavioural and clinical 
exercise cancer research. Even some of the most methodologically robust exercise 
intervention studies, assessing CV and functional outcomes during treatment, fail to 
mention the possible confounding influence of these medications (Courneya et al., 2008; 
Courneya et al., 2007; Courneya et al., 2009; Haykowsky, Mackey, Thompson, Jones, & 
Paterson, 2009; Mock et al., 2005; Mock et al., 2001; Pickett et al., 2002). Many patients 
undergoing chemotherapy are prescribed medications to alleviate pain, nausea, bowel 
irregularity, sleeplessness, depression, allergic reactions, boost blood cell counts and 
control inflammation. Given the possible CV and NS perturbations caused by these 
medications, it is surprising that their potential influence has been largely overlooked. 
After review of our patient medication use, we report the T1 incidence of potentially 
confounding medication (PCM) use in 2 of 13 patients (15.4%). Not surprisingly, T2 PCM 
use was reported in 10 of 12 patients (83.3%).  
 
To mitigate the influence of PCM (and to allow optimal recovery from the 
previous treatment), to the best of our ability, we attempted to complete the T2 
evaluation in the 3-6 days before the 5th cycle of chemotherapy. In doing so, we had 
hoped to avoid the confounding influence of PCM taken in support of the 4th cycle and in 
anticipation of the 5th. We were mostly successful in this effort with only 1 of 12 T2 
patient evaluations (16.7%) taking place the day before treatment. Importantly, the use 
of these supportive medications is not easily predictable and depends on patients’ 
symptom profile, treatment schedule and whether or not the symptom being managed is 
acutely related to therapy or a cancer-related life circumstance. Given our small sample 









Figure 18: Use of PCMs by phase 
 
 
Autonomic Testing: CASS 
CASS Component Results 
CASS component analysis revealed evidence of T1 cardiovagal impairment in 
5/12 (41.7%) of our patients [moderate impairment: 3/12 (25.0%), mild impairment: 2/12 
(16.7%)] compared to mild impairment in only 1/12 (8.3%) of our control group. QSART- 
evidence of sudomotor impairment was present at T1 in 4/13 (30.4%) of patients [severe 
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impairment: 2/13 (15.4%); moderate impairment 2/13 (15.4%)], compared to no 
evidence of impairment in the control group (see Table 12). No adrenergic dysfunction 
was evident at T1 in either group (see Table 12). 
 
At T2, CASS component analysis revealed persistent cardiovagal impairment in 
3/11 (27.3%) of patients [moderate impairment: 1/11 (9.1%); mild impairment 2/11 
(18.2%)] compared to a consistent mild impairment in 1/11 (9.1%) control group 
members (see Table 13). T2 sudomotor assessment revealed persistent evidence of 
impairment in 5/11 (45.5%) patients [moderate impairment: 4/11 (36.4%); mild 
impairment: 1/11 (9.1%) (see Table 12). Again, no evidence of adrenergic impairment 
was detected (Table 12). 
 
Preface: Results Interpretation (Figures 19-24) 
 In the following figures, the data points have been colour-coded within each 
group and according to subject. Circular data points reflect scores or measurements 
falling within normal age- and gender-related ranges. Whereas triangular and square 
data points reflect scores or measurements > 50% of lower limit and < 50% of lower 





























# Mild # Moderate 
# 
Severe 
Patients 13 0 2 2 12 1 4 0 
Controls 12 0 0 0 11 0 1 0 




















# Mild # Moderate 
# 
Severe 
Patients 12 2 3 0 11 2 1 0 
Controls 12 1 0 0 11 1 0 0 



















# Mild # Moderate 
# 
Severe 
Patient 11 0 0 0 12 0 0 0 
Control 12 0 0 0 11 0 0 0 



































Figure 24: QSART results - Foot 
 
 
Global CASS Results 
Autonomic dysfunction is defined as a minimum score of two in any of the three 
CASS domains (cardiovagal, adrenergic and sudomotor), or a minimum score of one in 
at least two domains (Low et al., 2004). Using these criteria, our assessment of ANS 
function revealed the occurrence of mild or moderate ANS disturbances at T1 (38.5% vs. 
0%) and T2 (33.3% vs. 9%) in patient and control groups, respectively (see Figures 19-
24 for raw and calculated ANS data, Table 13 for total CASS scores). CASS comparison 
at T1 and T2 (Table 13) suggested a partial resolution of the patients’ autonomic 












Table 13: CASS Scores 
 

















Patient 13 4 1 12 4 0 
Control 12 0 0 11 1 0 
 
% Affected T1 Patient 38.5% Control 0% 
% Affected T2 Patient 33.3% Control 9% 
 
 
Exercise Testing: Modified Astrand-Rhyming Cycle Ergometer 
 At T1, predicted VO2max performance appeared lower in the patient group (patient 
(M=2.54 ml O2kg
-1min-1, SD=0.70) than in controls (M=3.29 ml O2kg
-1min-1, 
SD=0.97); t(19)=2.022, p = 0.058), but the trend did not reach significance. At T2, 
predicted VO2max was significantly different between patient (M=2.5 ml O2kg
-1min-1), 
SD=0.66) and control (M=3.4 ml O2kg
-1min-1, SD=0.95) groups; t(19)=2.559, p = 0.019. 
A 2x2 repeated measures ANOVA did not reveal any significant changes in measured 
(HR, BP and RPE) or calculated (HR & BP rates of change, absolute or relative VO2max) 
endpoints between groups, across our two tests. There was, however, a significant 
effect of treatment on HR recovery [F(1,1) = 6.188, p = 0.027]. Similar to the direction of 





Feasibility of Autonomic Testing in Cancer 
Through this feasibility study, we have endeavoured to establish 
recommendations and guidelines upon which future investigations of ANS function in 
cancer can be mounted. Overall, we averaged 98.2% success in achieving our FC. As 
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such, we are confident that a larger scale investigation of potential cancer-related 
autonomic dysfunction is possible. Despite this success, and drawing from our collective 
experience, we propose the following methodological considerations for those wishing to 
pursue related lines of research. 
 
Methodological Considerations: Autonomic and Cardiovascular Testing in Cancer 
 
1. Patient Recruitment, Access and Retention 
a) Recruitment from a slightly expanded AYA age range (18-45 instead of 18-39) 
provided important recruitment opportunity and seemingly without exposing the sample 
to additional ANS or CV dysfunction and related use of medication.  
 
b) To achieve an adequate sample size, without the staunch support of primary 
care staff (oncologists & nurses), requires either an omnipresent study recruiter or 
soliciting the assistance of key administrative hospital personnel. In our case, the team 
responsible for booking chemotherapy appointments was a tremendous help in 
identifying potential patients. Investigations targeting specific cancer populations should 
make every effort to verify the volume of appropriate patients before opening a trial. In 
our experience, given the absence of underlying comorbidity, screening for age and Dx 
are likely sufficient. 
 
c) A cancer Dx is difficult at any age, AYA cancer being no exception. Despite the 
emotional onslaught following their Dx, AYAs appear highly motivated and capable of 
participating in studies of this nature. Bearing in mind that this was an observation trial, 
requiring an average of 3.5 hours for each of their two visits, we cannot generalize to the 
motivation and ability of AYAs to participate in intervention-based trials. 
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d) Additionally, at such a precarious time in life, the implementation of a reminder 
system (for pre-test protocol and appointment times) is likely an important component of 
AYA patient recruitment and retention. 
 
2. Establishing a Pre-Chemotherapy Baseline 
Using our clinical data, we had an idea of what our window of opportunity was to 
complete our T1 measures. Extrapolating from our own clinical/research experience and 
the literature, AYAs are at higher risk for being misdiagnosed or diagnosed late (Bleyer, 
2002, 2007) for a variety of reasons. Regardless of the reason, the likely consequence 
of a late Dx is an advanced staging at Dx, and subsequently aggressive treatment of the 
disease. Although we cannot report actual incidence data, reason suggests that these 
factors work to narrow the available T1-testing window. Accordingly, it is imperative that 
investigators devise a means of identifying and booking patients for testing before the 
likelihood of PCM use increases. Given our moderate success (73.3% of OEP) in 
recruiting (M=3.8 days post Dx) and testing (M=9.1 days post Dx) patients from across 
multiple clinics, we suggest that investigators make every effort to not fall below our 
reported averages. 
 
3. Test Performance and Tolerability 
Consistent with our expectations, although not statistically powered, we report no 
difference in test tolerability between groups. That two members of our AYA patients 
group presented with symptoms that prevented the completion of the entire test battery 
is simply a reflection of their clinical reality. Comparison of all attempted trials suggests 
no clinically relevant difference in test performance or tolerance between patients and 




4. Potentially Confounding Medication Use 
Again not statistically supported, we propose that, with the right planning, the 
influence of PCM on reported CV and NS patient outcomes may be minimized. Given 
the ease with which ANS function is perturbed, it is imperative that every effort is made 
to collect data within the period least likely to be influenced by PCM use. Supported by 
the partial resolution of ANS symptoms observed in our patient group at T2, we 
recommend that all in-treatment measures be collected within the 3-6 days prior to 
patients’ subsequent treatments (assuming the average dose cycle for your study 
population is between 2-3 weeks per cycle). A window of least influence may be much 
more difficult to identify for treatment protocols involving weekly doses of chemotherapy 
or for patients taking PCM for chronic conditions/symptom management (i.e. 
antidepressants and sleep-aids). As such, it is extremely important that the future 
reporting of human observation and intervention trials include PCM data. 
 
5. Varia 
In an effort to better characterize the relationship between aerobic fitness and 
ANS function in cancer, future investigations should consider including basic 
standardized assessments of each. However, based on the apparent lack of sensitivity 
of the single stage Astrand-Rhyming protocol, submaximal incremental ramp or maximal 
exercise testing protocols may be more appropriate. Finally, investigators should 
account for and report any differences in aerobic fitness as it may influence or predict 
cardiovagal performance. 
 
Autonomic Function in Cancer 
Contrary to our hypotheses, as demonstrated by CASS, patient ANS function 
appeared slightly more impaired at T1 than T2. Similarly, aerobic performance (as 
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evidenced by a T2 improvement in HR recovery) appeared worse at T1. Although 
predicted VO2max scores differed with greater significance at T2 (T1 (p=0.58) and T2 
(p=0.019)). 
 
The cardiovagal, adrenergic, and sudomotor CASS components reflect the 
integrity of parasympathetic, sympathetic, and sudomotor sympathetic branches of the 
ANS, respectively (Low, 1993b). Supporting the evidence for paraneoplastic-related 
autonomic dysfunction in cancer (Argyriou et al., 2005; Darnell & Posner, 2003; Nevruz 
et al., 2007; Turner et al., 1993; Viniegra et al., 1990; Walsh, Clark, Parhad, & Green, 
1982), our T1 assessment revealed evidence of ANS impairment. Contrary to reports of 
increased ANS impairment during or following treatment (Argyriou et al., 2005; Viniegra 
et al., 1990), and similar to the findings of Turner et al. (1993), our results demonstrated 
persistent, yet partially resolved, ANS dysfunction in our patient group at T2. Importantly, 
there is evidence supporting the correlation between higher resting parasympathetic 
tone and higher aerobic fitness levels (Barney et al., 1988; Davy et al., 1996; De 
Meersman, 1992, 1993; Dixon, Kamath, McCartney, & Fallen, 1992; Goldsmith, Bigger, 
Steinman, & Fleiss, 1992b; Levy et al., 1998; Seals & Chase, 1989; Stein et al., 1999). 
Accordingly, interpretation of our T1 and T2 measures of cardiovagal function must 
include the potential confounding influence of the observed differences in aerobic fitness 
between our groups. Contrary to reports of chemotherapy-induced HRV attenuation 
(Fadul et al., 2010; Fagundes et al., 2011; Hirvonen et al., 1989), spectral analysis of the 
short-term HRV recordings (obtained during pre-tilt rest) did not reveal any observable 
fluctuation in parasympathetic activity, as indicated by the high-frequency domain. 
However, this was consistent with the findings of Ekholm et al. (2000), who suggested 
that the acute chemotherapy-induced changes may be more subtle and therefore not as 
easily detected using short-term (vs. 24-hour) recordings. Finally, to the best of our 
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knowledge, we are the first to report QSART evidence of sudomotor impairment in 
cancer.  
 
Less clear is to what extent the observed ANS impairments will persist into 
survivorship and potentially impact the long-term quality of life of these patients. Related 
research has demonstrated persistent ANS impairment in cancer survivors, with and 
without advanced disease (Fadul et al., 2010; Fagundes et al., 2011; Hansen, 1990; 
Nuver et al., 2005; Strasser et al., 2006). If, in fact, cancer and anticancer therapy are 
responsible for causing long term ANS impairment or predisposing cancer survivors to 
related morbidity, the development of protective therapies is imperative. However, the 
reported testing methodologies of these studies varied in inclusion/exclusion criteria, 
ANS assessment techniques, as well as many did not control for known confounding 
comorbidities (i.e. diabetes and CVD) and related medications (i.e. various cardiac, 
antihypertensive and opioid use). Furthermore, in the absence of a pre-treatment 
baseline evaluation and the inclusion of a wide age-range of participants (19-79 years), it 
is difficult to assess whether the reported ANS impairments have resulted directly from 
the various cancers and anti-cancer therapies. 
 
CV exercise training has been shown to preserve and improve markers of ANS 
and CV health in other populations (Rosenwinkel et al., 2001). However, dysfunction of 
either the parasympathetic, sympathetic or sudomotor ANS branches may uniquely 
compromise the ability of affected cancer patients to exercise. More specifically, the shift 
toward a “sympathetic dominant ANS balance,” caused by either vagal withdrawal or 
sympathetic hyperactivity, predisposes individuals to chronically higher resting metabolic 
rates (Rosenwinkel et al., 2001; Thayer & Lane, 2007), and therein an energetically 
unfavourable position. Furthermore, parasympathetic damage may hinder early exercise 
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adaptations to (Arai et al., 1989; Goldsmith, 1991; Robinson et al., 1966; Rowell, 1993), 
and recovery rates from (Imai et al., 1994; Ohuchi et al., 2000; Pierpont et al., 2000; 
Sears et al., 1998), exercise. Inadequate sympathetic adjustments are known to cause 
maladaptive BP responses (Low, 1997) and may limit the attainment of ME performance 
(Christensen & Brandsborg, 1973; Orizio et al., 1988; Robinson et al., 1966; Rowell, 
1993). Finally, aberrant sweat responses, resulting from sudomotor dysfunction, may 
compromise thermoregulation and place exercising cancer patients at risk for heat injury 
(Bannister, Ardill, & Fentem, 1967) and related exercise intolerance. 
 
Unfortunately, due to limitations in our study design, we were unable to provide 
evidence of any relationship between CV performance changes and the observed ANS 
dysfunction. Possible reasons for this include: i) insensitivity of the modified, single stage 
Astrand-Rhyming protocol, ii) small sample size and iii) wide range of normal biologic 
variability within our control group. Additional study limitations include: i) heterogeneity of 
diseases and related-treatments, ii) reliance on predicted, and not measured, VO2max 
scores as indicators of aerobic fitness, iii) potential pre-test protocol violations, iv) 
inaccurate patient reported outcomes, v) the use of the BFI to compare across cancer 
and non-cancer populations and vi) unreported use of PCMs in our control group.  
 
Acute and chronic autonomic impairment has been shown to have deleterious 
effects on quality of life and survival in health and a variety of disease states (Thayer & 
Lane, 2007). Initial evidence of cancer- and chemotherapy-related ANS dysfunction has 
been shown here and in the literature (in both the patient and survivorship settings) 
(Argyriou et al., 2005; Ekholm et al., 1997; Ekholm et al., 2000; Fadul et al., 2010; 
Fagundes et al., 2011; Hansen, 1990; Hirvonen et al., 1989; Hrushesky et al., 1991; 
Morrow, 2000; Morrow, Hickok, DuBeshter, & Lipshultz, 1999; Nevruz et al., 2007; Nuver 
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et al., 2005; Strasser et al., 2006; Turner et al., 1993; Viniegra et al., 1990; Walsh et al., 
1982). However, without methodological consistency and standardization of 
assessment, accurate characterization of potential cancer- and chemotherapy-related 
autonomic damage is difficult. Considering the aforementioned methodological 
inconsistencies in previous ANS-cancer research, we had to rely upon methodologically 
robust, exercise oncology trials as the basis of our feasibility assessment. The utilization 
of exercise oncology trials as a foundation for our FC may be more relevant given the 
potential for using exercise as a modality to preserve and restore ANS and CV function 
in cancer, as has been described in other populations (Rosenwinkel et al., 2001). As 





The general aim of this study was to establish the feasibility of testing autonomic 
and CV function in AYA cancer patients undergoing treatment for cancer by: i) defining 
the methodological pitfalls and best-practice criteria for ANS testing in cancer, and ii) 
providing initial physiologic evidence of autonomic perturbations in cancer patients using 
the CASS. From a logistical standpoint, with a 98.5% average success rate in achieving 
the targeted FC, we are confident that future investigations of autonomic function in 
cancer are possible. However, given the multiplicity of confounding testing influences 
(i.e. lifestyle, age, comorbidity, cancer and the use of various anticancer therapies and 
supportive medications) the study of ANS function in cancer remains challenging. 
Cancer and chemotherapy are both known to impact effector organ function. As such, it 
may be necessary to conduct separate assessments effector organ function (i.e. multi 
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gated acquisition scans or pulmonary function tests) in an attempt to help localize 
cancer-related damage. Importantly, future investigations of autonomic and CV function, 
both during and following treatment, should make every effort to minimize the influence 
of PCM and to report PCM use whenever possible. Furthermore, to standardize the 
evaluation of ANS function in cancer, we strongly recommend the use of the CASS and 
components therein. Finally, contrary to our hypotheses, chemotherapy did not appear 
to significantly impair the autonomic responses to the CASS test battery. Although not 
statistically meaningful (due to small sample size), our main findings (diminished RSA 
and QSART) possibly suggest a common cholinergic mechanism of dysfunction. When 
considering the proposed mechanism of acetylcholine and vagal function inhibition of 
proinflammatory cytokine release (Tracey, 2002), it is interesting to speculate that if 
cancer-related parasympathetic dysfunction does exist, it may provide a pathway for 
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Incidence: approximately 10 000 
5-year Survival: 72 men & 81 women 






Incidence 38,339 62,035 
Survival 27,840 48,506 
Mortality 10,499 13,529 
Average life expectancy 79 83 
Average years of life 
lost/impacted 
47 51 
Average years of life 
impacted 
47 51 
Total years of life lost 493,453 689,979 





 Approximately > 350,000 years of life impacted (actual estimate 378,227) 






Cardiovascular toxicity of particular antineoplastic drugs. 
 







Overview of peripheral and central neurotoxic complications associated with 
various chemotherapy drugs 
 
 
(Verstappen, Heimans, Hoekman, & Postma, 2003) 
